<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006186.pub2" GROUP_ID="STROKE" ID="624205040513231282" MERGED_FROM="" MODIFIED="2011-03-07 15:31:53 +0100" MODIFIED_BY="Hazel Fraser" REVIEW_NO="0001" REVMAN_SUB_VERSION="5.0.25" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2011-03-07 15:31:53 +0100" MODIFIED_BY="Hazel Fraser">
<TITLE>Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks</TITLE>
<CONTACT MODIFIED="2011-03-07 15:31:53 +0100" MODIFIED_BY="Hazel Fraser"><PERSON ID="CC0260ED82E26AA2014E8D67A13AC6AB" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Maria</FIRST_NAME><MIDDLE_INITIALS>I</MIDDLE_INITIALS><LAST_NAME>Aguilar</LAST_NAME><SUFFIX>MD</SUFFIX><EMAIL_1>maria.aguilar@mayo.edu</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>Mayo Clinic Arizona</ORGANISATION><ADDRESS_1>5777 E. Mayo Boulevard</ADDRESS_1><CITY>Phoenix</CITY><ZIP>85022</ZIP><REGION>Arizona</REGION><COUNTRY CODE="US">USA</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2011-03-07 15:31:53 +0100" MODIFIED_BY="Hazel Fraser"><PERSON ID="CC0260ED82E26AA2014E8D67A13AC6AB" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Maria</FIRST_NAME><MIDDLE_INITIALS>I</MIDDLE_INITIALS><LAST_NAME>Aguilar</LAST_NAME><SUFFIX>MD</SUFFIX><EMAIL_1>maria.aguilar@mayo.edu</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>Mayo Clinic Arizona</ORGANISATION><ADDRESS_1>5777 E. Mayo Boulevard</ADDRESS_1><CITY>Phoenix</CITY><ZIP>85022</ZIP><REGION>Arizona</REGION><COUNTRY CODE="US">USA</COUNTRY></ADDRESS></PERSON><PERSON ID="9230" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Robert</FIRST_NAME><LAST_NAME>Hart</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Professor of Medicine (Neurology)</POSITION><EMAIL_1>hartr@uthscsa.edu</EMAIL_1><ADDRESS><DEPARTMENT>Division of Neurology, Department of Medicine</DEPARTMENT><ORGANISATION>University of Texas Health Science Center at San Antonio</ORGANISATION><ADDRESS_1>7703 Floyd Curl Drive</ADDRESS_1><CITY>San Antonio</CITY><ZIP>78284-7883</ZIP><REGION>Texas</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 210 6175161</PHONE_1><PHONE_2>+1 210 5920404</PHONE_2><FAX_1>+1 210 5674659</FAX_1></ADDRESS></PERSON><PERSON ID="219E9E7582E26AA200831C195D014F0A" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Lesly</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Pearce</LAST_NAME><SUFFIX>MS</SUFFIX><EMAIL_1>lpearce@minot.com</EMAIL_1><ADDRESS><ORGANISATION>Biostatistics Consultant</ORGANISATION><ADDRESS_1>2509 Bel Air Court</ADDRESS_1><CITY>Minot</CITY><ZIP>58703</ZIP><REGION>North Dakota</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 701 852 1978</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-09-09 15:50:06 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="14" MONTH="9" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="30" MONTH="6" YEAR="2006"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="4" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2011-03-07 14:28:37 +0000" MODIFIED_BY="Hazel Fraser">
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2011-03-07 14:28:37 +0000" MODIFIED_BY="Hazel Fraser">
<DATE DAY="7" MONTH="3" YEAR="2011"/>
<DESCRIPTION>
<P>Link to feedback added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2011-03-07 14:28:21 +0000" MODIFIED_BY="Hazel Fraser">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-03-07 14:28:21 +0000" MODIFIED_BY="Hazel Fraser">
<DATE DAY="9" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-09-09 15:57:13 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY>
<TITLE>Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks</TITLE>
<SUMMARY_BODY>
<P>Atrial fibrillation (AF) is an irregularity of the heartbeat that leads to blood clots forming in the upper chambers of the heart (the atria). These clots can break free and travel through the bloodstream to the brain and cause a stroke. Drugs that slow clotting, such as oral anticoagulants (warfarin and other coumarin derivates) and antiplatelet agents (aspirin and others), reduce the risk of stroke in patients with atrial fibrillation. In this review of eight randomized trials, including 9598 patients, oral anticoagulants are shown to reduce the risk of stroke in patients with non-valvular AF and with no prior stroke or transient ischemic attack by one-third when compared with antiplatelet agents alone. Antiplatelet agents reduce stroke by about 20% in AF patients compared with no therapy, offering a less efficacious therapeutic option for those deemed not eligible for anticoagulation therapy. The threshold of absolute benefit that warrants anticoagulation remains controversial and depends on patient's preferences and availability of optimal anticoagulation monitoring.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Non-valvular atrial fibrillation (AF) carries an increased risk of stroke mediated by embolism of stasis-precipitated thrombi originating in the left atrial appendage. Both oral anticoagulants and antiplatelet agents have proven effective for stroke prevention in most patients at high risk for vascular events, but primary stroke prevention in patients with non-valvular AF potentially merits separate consideration because of the suspected cardio-embolic mechanism of most strokes in AF patients.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To characterize the relative effect of long-term oral anticoagulant treatment compared with antiplatelet therapy on major vascular events in patients with non-valvular AF and no history of stroke or transient ischemic attack (TIA).</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Stroke Group Trials Register (June 2006). We also searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> Issue 2, 2006), MEDLINE (1966 to June 2006) and EMBASE (1980 to June 2006). We contacted the Atrial Fibrillation Collaboration and experts working in the field to identify unpublished and ongoing trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All unconfounded, randomized trials in which long-term (more than four weeks) adjusted-dose oral anticoagulant treatment was compared with antiplatelet therapy in patients with chronic non-valvular AF.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two review authors independently selected trials for inclusion, assessed quality and extracted data. The Peto method was used for combining odds ratios after assessing for heterogeneity.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Eight randomized trials, including 9598 patients, tested adjusted-dose warfarin versus aspirin (in dosages ranging from 75 to 325 mg/day) in AF patients without prior stroke or TIA. The mean overall follow up was 1.9 years/participant. Oral anticoagulants were associated with lower risk of all stroke (odds ratio (OR) 0.68, 95% confidence interval (CI) 0.54 to 0.85), ischemic stroke (OR 0.53, 95% CI 0.41 to 0.68) and systemic emboli (OR 0.48, 95% CI 0.25 to 0.90). All disabling or fatal strokes (OR 0.71, 95% CI 0.59 to 1.04) and myocardial infarction (OR 0.69, 95% CI 0.47 to 1.01) were substantially but not significantly reduced by oral anticoagulants. Vascular death (OR 0.93, 95% CI 0.75 to 1.15) and all cause mortality (OR 0.99, 95% CI 0.83 to 1.18), were similar with these treatments. Intracranial hemorrhages (OR 1.98, 95% CI 1.20 to 3.28) were increased by oral anticoagulant therapy. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Adjusted-dose warfarin and related oral anticoagulants reduce stroke, disabling stroke and other major vascular events for those with non-valvular AF by about one third when compared with antiplatelet therapy. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-09-09 15:57:13 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>Non-valvular atrial fibrillation (AF) is a common cardiac arrhythmia, affecting about 0.7% of the general population (<LINK REF="REF-Feinberg-1995" TYPE="REFERENCE">Feinberg 1995</LINK>; <LINK REF="REF-Go-2001" TYPE="REFERENCE">Go 2001</LINK>). Its prevalence increases with age; about 5% of people over age 65 years and 10% of people over the age of 80 years suffer from AF (<LINK REF="REF-Feinberg-1995" TYPE="REFERENCE">Feinberg 1995</LINK>). </P>
<P>AF is the most common cause of cardio-embolic stroke and is a powerful independent risk factor for cerebral ischemia. It is associated with about 16% of all ischemic strokes and is a frequent cause of disabling stroke in the elderly, particularly in women (<LINK REF="REF-Wolf--1991" TYPE="REFERENCE">Wolf 1991</LINK>). The overall risk of stroke among non-anticoagulated patients with AF without prior stroke or transient ischemic attack (TIA) was about 4% per year among participants in clinical trials (<LINK REF="REF-AFI-1994" TYPE="REFERENCE">AFI 1994</LINK>) and 2.5% per year in a large outpatient cohort (<LINK REF="REF-Go-2003" TYPE="REFERENCE">Go 2003</LINK>). </P>
<P>The rate of stroke varies widely, depending on co-existing cardiovascular disorders. Identification of subgroups of AF patients with relatively high versus low absolute rates of stroke is important for selecting the appropriate prophylactic therapy. Prospective studies have shown that age, hypertension, prior TIA or stroke, diabetes, and female gender are independently predictive of stroke in AF patients and significantly increase the stroke risk (<LINK REF="REF-Gage-2001" TYPE="REFERENCE">Gage 2001</LINK>; <LINK REF="REF-Hart-1999" TYPE="REFERENCE">Hart 1999</LINK>; <LINK REF="REF-Wang-2003" TYPE="REFERENCE">Wang 2003</LINK>). </P>
<P>Aspirin reduces stroke and other major vascular events for those with non-valvular AF compared with no antithrombotic treatment, but the effect is modest (about 25%). Adjusted-dose warfarin offers larger, more predictable reductions in stroke for AF patients who can safely receive it (<LINK REF="REF-Aguilar-2006a" TYPE="REFERENCE">Aguilar 2006a</LINK>; <LINK REF="REF-Aguilar-2006b" TYPE="REFERENCE">Aguilar 2006b</LINK>; <LINK REF="REF-Van-Walraven-2002" TYPE="REFERENCE">Van Walraven 2002</LINK>). Maximum protection against ischemic stroke in patients with AF is known to be achieved by maintaining the international normalized ratio (INR) between 2.0 and 3.0 (<LINK REF="REF-Hylek-2003" TYPE="REFERENCE">Hylek 2003</LINK>; <LINK REF="REF-Oden-2006" TYPE="REFERENCE">Oden 2006</LINK>). </P>
<P>Most guidelines recommend adjusted-dose warfarin for AF patients at high risk for stroke and aspirin for those deemed at low risk or for those who cannot safely receive adjusted-dose warfarin. Stroke risk stratification schemes have been developed and validated for AF patients that allow reliable classification of risk (<LINK REF="REF-Gage-2004" TYPE="REFERENCE">Gage 2004</LINK>; <LINK REF="REF-Go-2003" TYPE="REFERENCE">Go 2003</LINK>; <LINK REF="REF-Hart-2003" TYPE="REFERENCE">Hart 2003</LINK>). The threshold of benefit that would warrant anticoagulation remains controversial and depends on patient preferences and availability of optimal anticoagulation monitoring. In most cohorts of AF patients without prior stroke or TIA, 30% to 50% have sufficiently low stroke rates during antiplatelet therapy that the absolute benefits of anticoagulation would be small (less than 1% per year) (<LINK REF="REF-Hart-2003" TYPE="REFERENCE">Hart 2003</LINK>). </P>
<P>Taylor and colleagues (<LINK REF="REF-Taylor-2001" TYPE="REFERENCE">Taylor 2001</LINK>) conducted a systematic review of oral anticoagulants versus antiplatelet therapy in AF patients in 2001, including five randomized controlled trials. Primary and secondary prevention trials were combined in their analysis. Results were deemed heterogeneous and the value of long-term anticoagulation compared with antiplatelet therapy was labelled 'uncertain'. Van Walraven (<LINK REF="REF-Van-Walraven-2002" TYPE="REFERENCE">Van Walraven 2002</LINK>) and colleagues have also published a pooled analysis of oral anticoagulant versus aspirin in non-valvular AF. Again, both primary and secondary prevention trials were included. We are aware, anecdotally, of additional trials that have appeared since the publication of these two studies.</P>
<P>This systematic review includes all randomized trials of adjusted-dose achieved (INR &#8805; 1.6) oral anticoagulants versus antiplatelet therapy for the primary prevention of stroke and other major vascular events in patients with non-valvular atrial fibrillation. <BR/>
<BR/>Our goals were to determine whether there is clear evidence that oral anticoagulant treatment is efficacious, superior and safe relative to antiplatelet therapy in these patients and to characterize the magnitude of benefit. </P>
</BACKGROUND>
<OBJECTIVES>
<P>To characterize the relative effect of long-term oral anticoagulant treatment versus antiplatelet therapy on major vascular events in patients with non-valvular AF and no history of stroke or TIA. Our main hypotheses were:<BR/>(1) oral anticoagulant treatment compared with antiplatelet therapy reduces ischemic events: ischemic strokes, myocardial infarction, systemic emboli, and vascular death (with a smaller decrease in all-cause death);<BR/>(2) oral anticoagulant treatment compared with antiplatelet therapy increases bleeding events: intracranial hemorrhage and major extracranial hemorrhage;<BR/>(3) oral anticoagulant treatment compared to antiplatelet therapy decreases clinically relevant combinations of ischemic plus bleeding events: all stroke (ischemic and hemorrhagic), disabling or fatal stroke (ischemic and hemorrhagic), and the composite of all stroke, myocardial infarction or vascular death. </P>
</OBJECTIVES>
<METHODS MODIFIED="2008-09-09 15:55:00 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-09-09 15:51:56 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>We identified all unconfounded, randomized trials in which long-term (more than four weeks) adjusted-dose oral anticoagulant treatment was compared with antiplatelet therapy in patients with chronic non-valvular AF. We considered trials in which the intervention was masked (double-blinded, where both the clinician and the patient are unaware of the intervention) and those in which the intervention was given open label. We excluded trials involving iatrogenic cardioversion for recent onset AF.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>We included participants with AF documented by electrocardiogram (ECG), either intermittent (paroxysmal) or sustained (constant). We did not include those with concomitant mitral stenosis or prosthetic cardiac valves.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>We considered adjusted-dose warfarin (to INR &gt; 1.5) or other coumarins (such as acenocumarol) and aspirin (acetylsalicylic acid) or other specific platelet antiaggregants given in any dose, formulation, combination, or frequency. Antiplatelet therapy included agents whose primary antithrombotic action is presumed to be inhibition of platelet aggregation (eg aspirin, clopidogrel, ticlopidine, dipyridamole, indobufen, triflusal).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-09-09 15:51:56 +0100" MODIFIED_BY="[Empty name]">
<P>We chose 10 clinically relevant outcomes that are hypothesized to be influenced by antithrombotic therapies. Each outcome was measured at the end of the study follow-up period.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<P>(1) All strokes (ischemic and hemorrhagic). We deemed it the most relevant outcome for a disorder whose main health threat is stroke: that is, patients with AF take antithrombotic therapy to prevent stroke.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">(1) Ischemic strokes (including both fatal and non-fatal)</HEADING>
<P>Diagnosis based on clinical features and in most cases, neuroimaging or autopsy. We anticipated unknown strokes without neuroimaging to be a minority and counted them as ischemic strokes. We did not include asymptomatic brain infarcts detected on neuroimaging. We counted hemorrhagic transformation of ischemic strokes as ischemic strokes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(2) All disabling or fatal strokes (ischemic and hemorrhagic)</HEADING>
<P>We considered strokes fatal when death ensued within 30 days of onset from the consequences of stroke. We considered functional neurological deficits affecting activities of daily living and persisting one to three months after stroke onset as disabling strokes (that is, Rankin score &#8805; 2).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(3) Myocardial infarction (fatal and non-fatal)</HEADING>
<P>The diagnosis of myocardial infarction was based upon electrocardiographic changes, elevation of enzymes or confirmed during post-mortem examination.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(4) Systemic (that is, non-CNS) emboli</HEADING>
<P>Symptomatic cardio-embolic arterial occlusions involving areas other than the brain. We did not include non-cardio embolic arterial occlusions, nor pulmonary embolism.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(5) All intracranial hemorrhages</HEADING>
<P>This included intraparenchymal, subdural and epidural hematomas and subarachnoid hemorrhage based on clinical diagnosis by the investigators and confirmed by computerized tomography (CT) scan or post-mortem examination.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(6) Major extracranial hemorrhage</HEADING>
<P>We included those which required transfusion of two or more units of red blood cells, hospitalization, or invasive procedures to control bleeding, and those that resulted in death or permanent functional impairment (such as blindness).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(7) Vascular death</HEADING>
<P>These consisted of death due to stroke, heart disease, hemorrhage, and sudden deaths of unknown cause.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(8) Composite outcome</HEADING>
<P>All strokes (disabling and non-disabling, hemorrhagic and ischemic), myocardial infarction or vascular death.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">(9) All cause mortality</HEADING>
<P>Death from any cause (vascular and non-vascular) within 30 days from onset of stroke symptoms.</P>
</SUBSECTION>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-09-09 15:54:14 +0100" MODIFIED_BY="[Empty name]">
<P>See: 'Specialized register' section in <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/STROKE/frame.html">Cochrane Stroke Group</A>
</P>
<P>We searched the Cochrane Stroke Group Trials Register, which was last searched by the Review Group Co-ordinator in June 2006. In addition, we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> Issue 2, 2006), MEDLINE (1966 to June 2006) and EMBASE (1980 to June 2006) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>). The reference lists of relevant trials and recent review articles were reviewed. We also contacted the Atrial Fibrillation Collaboration (AFI) and experts working in the field to identify unpublished and ongoing trials.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-09-09 15:55:00 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors independently assessed trials for potential inclusion, and abstracted the outcomes of interest from published sources. We extracted details of the inclusion and exclusion criteria, method of randomization, masked versus open-label intervention, antithrombotic agents in the control group, losses to follow up, adherence to assigned therapy, and intention-to-treat design; we used intention-to-treat results whenever possible.</P>
<P>We did not include comparisons of low, fixed-dose warfarin with antiplatelet therapy because the efficacy of warfarin is well documented to be dependent on INR prolongation. We also excluded trials comparing adjusted-dose warfarin with antiplatelet therapy plus low, fixed-dose warfarin.<BR/>
<I>
<BR/>
</I>We assessed trial quality based on CONSORT statement recommendations (<LINK REF="REF-CONSORT-2001" TYPE="REFERENCE">CONSORT 2001</LINK>). We assigned a score of one when the criteria were fulfilled; a score of zero was assigned when the criteria were either not reported or not fulfilled adequately.</P>
<SUBSECTION>
<HEADING LEVEL="3">Criteria</HEADING>
<P>(1) Detailed eligibility criteria<BR/>(2) Specific intervention<BR/>(3) Pre-defined primary and secondary outcome<BR/>(4) Randomization method specific<BR/>(5) Allocation blocked from pre-viewing<BR/>(6) Blinded (ie masked) treatment<BR/>
</P>
<UL>
<LI>clinician</LI>
<LI>patient</LI>
</UL>
<P>(7) Intention-to-treat analysis<BR/>(8) Withdrawal rate<BR/>(9) Lost to follow up<BR/>(10) Baseline features balanced<BR/>(11) Fraction of strokes with neuroimaging or autopsy confirmation as ischemic versus hemorrhagic</P>
<P>Trial quality is presented by describing study methods (randomization, blinding, losses to follow up, etc), participants, intervention, outcomes and allocation concealment. We resolved any differences by conjoint review and discussion.</P>
<P>We used the Peto method, which assumes a fixed-effect model, to estimate the overall odds ratio (OR) and 95% confidence intervals (CI). We assessed the homogeneity of trial results using the Cochrane Q statistic and I-squared (I<SUP>2</SUP>) statistic (percentage of total variation across studies due to heterogeneity) (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). Statistical significance was accepted at the 0.05 level. We used the Cochrane Review Manager software (RevMan 4.2) for all analyses.</P>
<P>We did not perform any sensitivity analyses. In our protocol, we had planned to do three analyses but, after abstracting and reviewing the data, we did not do these for several reasons.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Analysis of trials in which aspirin was used as an antiplatelet agent compared with those where a non-aspirin antiplatelet agent was used</HEADING>
<P>
<LINK REF="STD-NASPEAF" TYPE="STUDY">NASPEAF</LINK> used a single non-aspirin antiplatelet agent and <LINK REF="STD-ACTIVE-W" TYPE="STUDY">ACTIVE W</LINK> used a combination of aspirin and a non-active antiplatelet agent, and the remaining six trials used aspirin as the antiplatelet agent. For the outcomes 01.01 to 01.06 and 01.08 I<SUP>2</SUP> was 0% across all eight trials, so we opted not to do the subgroup analysis comparing the one or two trials with the remaining six. For outcome 01.07, I<SUP>2</SUP> was substantial, and after reviewing the data and the literature, the heterogeneity seemed most likely due to the combination of antiplatelets used, rather than a non-aspirin antiplatelet agent being part of the combination in the <LINK REF="STD-ACTIVE-W" TYPE="STUDY">ACTIVE W</LINK> trial.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Analysis of trials in which monotherapy antiplatelet therapy was used compared with those using a combination antiplatelet therapy (such as aspirin plus clopidogrel)</HEADING>
<P>The <LINK REF="STD-ACTIVE-W" TYPE="STUDY">ACTIVE W</LINK> trial was the only trial of the eight included in the review which used a combination antiplatelet therapy. The I<SUP>2</SUP> statistic was 0% for outcomes 01.01 to 01.06 and 01.08, so we did not proceed with this subgroup analysis except for outcome 01.07, which we reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Analysis of trials in which more than 50% of INRs were within the trial specific target INR range (a marker of quality of anticoagulation) compared with those in which less than 50% of INRs were within the target range</HEADING>
<P>Six trials (<LINK REF="STD-ACTIVE-W" TYPE="STUDY">ACTIVE W</LINK>; <LINK REF="STD-AFASAK-II" TYPE="STUDY">AFASAK II</LINK>; <LINK REF="STD-ATHENS" TYPE="STUDY">ATHENS</LINK>; <LINK REF="STD-NASPEAF" TYPE="STUDY">NASPEAF</LINK>; <LINK REF="STD-SPAF-IIa" TYPE="STUDY">SPAF IIa</LINK>; <LINK REF="STD-SPAF-IIb" TYPE="STUDY">SPAF IIb</LINK>) reported more than 50% of INRs within the trial specific target INR range. Too few events occurred in the two trials (<LINK REF="STD-AFASAK-I" TYPE="STUDY">AFASAK I</LINK>; <LINK REF="STD-PATAF" TYPE="STUDY">PATAF</LINK>) with INRs in target less than 50% of the time to permit meaningful analysis.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-09-09 15:57:13 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION>
<P>We included results from eight trials in the main analyses: the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (<LINK REF="STD-ACTIVE-W" TYPE="STUDY">ACTIVE W</LINK>) (6706 participants); the Atrial Fibrillation, ASpirin, AntiKoagulation (<LINK REF="STD-AFASAK-I" TYPE="STUDY">AFASAK I</LINK>) trial (671 participants); the fixed minidose warfarin and aspirin alone and in combination versus adjusted-dose warfarin for stroke prevention in atrial fibrillation trial (<LINK REF="STD-AFASAK-II" TYPE="STUDY">AFASAK II</LINK>) (339 participants); the primary prevention of arterial thromboembolism in the oldest old with atrial fibrillation trial (<LINK REF="STD-ATHENS" TYPE="STUDY">ATHENS</LINK>) (31 participants); the comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation trial (<LINK REF="STD-NASPEAF" TYPE="STUDY">NASPEAF</LINK>) (479 participants); the Primary prevention of Arterial Thromboembolism in non-rheumatic Atrial Fibrillation in primary care (<LINK REF="STD-PATAF" TYPE="STUDY">PATAF</LINK>) trial (272 participants); and both parallel age-stratified trials comprising the Stroke Prevention in Atrial Fibrillation II study, <LINK REF="STD-SPAF-IIa" TYPE="STUDY">SPAF IIa</LINK> (715 participants) and <LINK REF="STD-SPAF-IIb" TYPE="STUDY">SPAF IIb</LINK> (385 participants). <LINK REF="STD-ACTIVE-W" TYPE="STUDY">ACTIVE W</LINK> (2003 to 2005) was a multicenter trial conducted in Asia, Australia, Europe, North and South America, and South Africa; <LINK REF="STD-AFASAK-I" TYPE="STUDY">AFASAK I</LINK> (1985 to 1988) and <LINK REF="STD-AFASAK-II" TYPE="STUDY">AFASAK II</LINK> (1992 to 1996) were done in Copenhagen, Denmark; <LINK REF="STD-ATHENS" TYPE="STUDY">ATHENS</LINK> (1996) was done in Athens, Greece; <LINK REF="STD-NASPEAF" TYPE="STUDY">NASPEAF</LINK> (1995 to 2000) was conducted in Spain; <LINK REF="STD-PATAF" TYPE="STUDY">PATAF</LINK> (1990 to 1996) took place in the Netherlands; and <LINK REF="STD-SPAF-IIa" TYPE="STUDY">SPAF IIa</LINK> and <LINK REF="STD-SPAF-IIb" TYPE="STUDY">SPAF IIb</LINK> were multicenter trials (1987 to 1992) conducted in the USA and Canada. <LINK REF="STD-NASPEAF" TYPE="STUDY">NASPEAF</LINK> included patients with valvular AF due to mitral stenosis, but this subgroup is not considered in the current analyses.</P>
<P>All trials used warfarin as the oral anticoagulant except <LINK REF="STD-NASPEAF" TYPE="STUDY">NASPEAF</LINK>, which used acenocumarol, and <LINK REF="STD-PATAF" TYPE="STUDY">PATAF</LINK>, which used several oral anticoagulants including warfarin. Target INRs ranged from 1.6 to 4.2 and achieved INRs were reported within range over 60% of the time for all trials except <LINK REF="STD-AFASAK-I" TYPE="STUDY">AFASAK I</LINK> (31% to 42%) and <LINK REF="STD-PATAF" TYPE="STUDY">PATAF</LINK> (48%). Aspirin was the antiplatelet agent tested, except <LINK REF="STD-ACTIVE-W" TYPE="STUDY">ACTIVE W</LINK>, which tested the combination of aspirin plus clopidogrel, and <LINK REF="STD-NASPEAF" TYPE="STUDY">NASPEAF</LINK>, which tested triflusal. The dosage of aspirin ranged from 75 mg per day to 325 mg per day.</P>
<P>All trials had open allocation to oral anticoagulants and most trials had open allocation to antiplatelet therapy except for <LINK REF="STD-AFASAK-I" TYPE="STUDY">AFASAK I</LINK>, in which it was masked whether aspirin or placebo was administered (only aspirin patients are included in this analysis).</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>The methodological quality of the eight trials appeared comparable (<I>see</I> Study quality assessment: <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Baseline features were balanced in all trials except for the small <LINK REF="STD-ATHENS" TYPE="STUDY">ATHENS</LINK> trial, in which the proportion of patients with heart failure and coronary artery disease was higher (more than twice) in the antiplatelet therapy arm, and the opposite occurred with diabetes (twice as high in the oral anticoagulant arm), but these imbalances were not statistically significant due to the small number of participants.</P>
<P>The randomization allocation sequence was concealed in <LINK REF="STD-NASPEAF" TYPE="STUDY">NASPEAF</LINK>, <LINK REF="STD-SPAF-IIa" TYPE="STUDY">SPAF IIa</LINK>, and <LINK REF="STD-SPAF-IIb" TYPE="STUDY">SPAF IIb</LINK>; status was not stated for the remaining trials. The fraction of participants lost to follow up was 9% in <LINK REF="STD-AFASAK-II" TYPE="STUDY">AFASAK II</LINK>, 4% in <LINK REF="STD-NASPEAF" TYPE="STUDY">NASPEAF</LINK> and 0.4% in both <LINK REF="STD-SPAF-IIa" TYPE="STUDY">SPAF IIa</LINK> and <LINK REF="STD-SPAF-IIb" TYPE="STUDY">SPAF IIb</LINK>. No patients were lost to follow up in <LINK REF="STD-PATAF" TYPE="STUDY">PATAF</LINK>, and it was not reported in <LINK REF="STD-ACTIVE-W" TYPE="STUDY">ACTIVE W</LINK>, <LINK REF="STD-AFASAK-I" TYPE="STUDY">AFASAK I</LINK> or <LINK REF="STD-ATHENS" TYPE="STUDY">ATHENS</LINK>. Rates of withdrawal from assigned therapy were 10% in <LINK REF="STD-ACTIVE-W" TYPE="STUDY">ACTIVE W</LINK>, 25% in <LINK REF="STD-AFASAK-I" TYPE="STUDY">AFASAK I</LINK>, 17% in <LINK REF="STD-AFASAK-II" TYPE="STUDY">AFASAK II</LINK>, none in <LINK REF="STD-ATHENS" TYPE="STUDY">ATHENS</LINK>, 18% in <LINK REF="STD-NASPEAF" TYPE="STUDY">NASPEAF</LINK>, 23% in <LINK REF="STD-PATAF" TYPE="STUDY">PATAF</LINK>, 15% in <LINK REF="STD-SPAF-IIa" TYPE="STUDY">SPAF IIa</LINK> and 14% in <LINK REF="STD-SPAF-IIb" TYPE="STUDY">SPAF IIb</LINK>. </P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-09-09 15:57:13 +0100" MODIFIED_BY="[Empty name]">
<P>The eight trials included 9598 AF participants, most (approximately 90%) without previous stroke or TIA. The fraction of participants with prior stroke or TIA was 15% in <LINK REF="STD-ACTIVE-W" TYPE="STUDY">ACTIVE W</LINK>, 5% in <LINK REF="STD-AFASAK-I" TYPE="STUDY">AFASAK I</LINK>, 8% in <LINK REF="STD-AFASAK-II" TYPE="STUDY">AFASAK II</LINK>, 6% in <LINK REF="STD-SPAF-IIa" TYPE="STUDY">SPAF IIa</LINK> , 9% in <LINK REF="STD-SPAF-IIb" TYPE="STUDY">SPAF IIb</LINK>, and none in the remaining trials. Results for participants with prior stroke or TIA could not be separated based on published data, and hence are included in the analyses; about 10% of participants had prior stroke or TIA. The mean overall follow up was 1.9 years per participant, resulting in about 18,236 patient years of observation.</P>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 1.1: All stroke (ischemic and hemorrhagic)</HEADING>
<P>Oral anticoagulants were associated with a significant (P = 0.0007) reduction in all stroke (OR 0.68, 95% CI 0.54 to 0.85; P = 0.80 for homogeneity, I<SUP>2</SUP> = 0%). Assuming an estimated annualized rate of stroke of 4% per year on antiplatelet therapy for primary prevention, about 13 strokes per year would be prevented for every 1000 AF patients given oral anticoagulants instead of antiplatelet therapy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 1.2: Ischemic strokes (fatal and non-fatal)</HEADING>
<P>Ischemic stroke was significantly (P &#8804; 0.00001) less frequent in those assigned to oral anticoagulants (OR 0.53, 95% CI 0.41 to 0.68, P = 0.51 for homogeneity, I<SUP>2</SUP> = 0%). Assuming an estimated annualized rate of ischemic stroke of 4% per year on antiplatelet therapy for primary prevention, about 19 events per year would be prevented for every 1000 AF patients given oral anticoagulants instead of antiplatelet therapy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 1.3: All disabling or fatal strokes (ischemic and hemorrhagic)</HEADING>
<P>Disabling or fatal stroke was also reduced by oral anticoagulants (OR 0.79, 95% CI 0.59 to 1.04, P = 0.78 for homogeneity, I<SUP>2</SUP> = 0%), although the results did not achieve statistical significance (P = 0.09). This outcome was not reported in the small <LINK REF="STD-ATHENS" TYPE="STUDY">ATHENS</LINK> trial.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 1.4: Myocardial infarction (fatal and non-fatal) </HEADING>
<P>Myocardial infarction was non-significantly (P = 0.06) reduced by oral anticoagulants (OR 0.69, 95% CI 0.47 to 1.01, P = 0.94 for homogeneity, I<SUP>2 </SUP>= 0%).This outcome was not recorded in <LINK REF="STD-AFASAK-I" TYPE="STUDY">AFASAK I</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 1.5: Systemic (non-CNS) emboli</HEADING>
<P>A total of 38 systemic emboli were reported. Frequency of these events was significantly reduced (P = 0.02) by oral anticoagulants (OR 0.48, 95% CI 0.25 to 0.90; P = 0.55 for homogeneity, I<SUP>2</SUP> = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 1.6: All intracranial hemorrhages</HEADING>
<P>Forty-one intracranial hemorrhages were reported in the oral anticoagulant group with significantly (P = 0.008) fewer (20 events) in the antiplatelet group (OR 1.98, 95% CI 1.20 to 3.28; P = 0.98 for homogeneity, I<SUP>2</SUP> = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 1.7: Major extracranial hemorrhage</HEADING>
<P>Results from the eight trials were not combined due to significant heterogeneity (P = 0.04, I<SUP>2</SUP> = 55.6%). Excluding <LINK REF="STD-ACTIVE-W" TYPE="STUDY">ACTIVE W</LINK> (which tested combined antiplatelet therapy with aspirin plus clopidogrel, known to increase bleeding relative to monotherapy), results indicated increased (P = 0.03) major extracranial hemorrhage in those treated with oral anticoagulants relative to those treated with antiplatelet therapy (OR 1.90, 95% CI 1.07 to 3.39; P = 0.24 for homogeneity, I<SUP>2</SUP> = 26.4%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 1.8: Vascular death</HEADING>
<P>No difference (P = 0.50) between oral anticoagulants and antiplatelet agents was evident (OR 0.93, 95% CI 0.75 to 1.15; P = 0.89 for homogeneity, I<SUP>2</SUP> = 0%). This outcome was not recorded in <LINK REF="STD-AFASAK-I" TYPE="STUDY">AFASAK I</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 1.9: Composite outcome: all strokes, myocardial infarction, or vascular death</HEADING>
<P>This outcome was not reported in <LINK REF="STD-AFASAK-I" TYPE="STUDY">AFASAK I</LINK>, <LINK REF="STD-PATAF" TYPE="STUDY">PATAF</LINK>, <LINK REF="STD-SPAF-IIa" TYPE="STUDY">SPAF IIa</LINK> or <LINK REF="STD-SPAF-IIb" TYPE="STUDY">SPAF IIb</LINK>. Considering results from the remaining four trials, oral anticoagulants significantly reduced (P = 0.003) the frequency of this composite outcome (OR 0.74, 95% CI 0.61 to 0.90; P = 0.33 for homogeneity, I<SUP>2</SUP> = 9.2%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 1.10: All cause mortality</HEADING>
<P>541 deaths occurred among 8927 participants in seven trials, with no difference (P = 0.91) between the two interventions observed (OR 0.99, 95% CI 0.83 to 1.18; P = 0.82 for homogeneity, I<SUP>2</SUP> = 0%). Mortality results were not reported in <LINK REF="STD-AFASAK-I" TYPE="STUDY">AFASAK I</LINK>.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>This meta-analysis of eight randomized clinical trials of non-valvular AF patients involving primary prevention demonstrates that oral anticoagulants are associated with a generally consistent and statistically significant relative reduction in stroke and other ischemic events relative to antiplatelet therapy. Intracranial hemorrhage was infrequent but it was significantly more common in those given oral anticoagulants compared with the antiplatelet group. Trial results for non-CNS major bleeds were heterogeneous due to the results of <LINK REF="STD-ACTIVE-W" TYPE="STUDY">ACTIVE W</LINK>, which used dual antiplatelet therapy instead of a single antiplatelet agent. In the meta-analysis of the remaining seven trials, major extracranial hemorrhages were more common in the oral anticoagulant group. These results suggest that the combination of aspirin plus clopidogrel carries a much higher risk of extracranial bleeding than aspirin alone, and this construct has been confirmed in a large randomized trial of patients with vascular disorders (<LINK REF="REF-CHARISMA-2006" TYPE="REFERENCE">CHARISMA 2006</LINK>).</P>
<P>Considering results from all available relevant randomized trials, oral anticoagulants reduce stroke in AF patients more effectively than antiplatelets, reducing ischemic strokes by half and doubling the less frequent hemorrhagic strokes for an overall net reduction. We regard the best estimate of the effect of oral anticoagulants versus antiplatelet therapy on all strokes (hemorrhagic and ischemic) in AF patients to be derived from all available randomized trials including trials of both primary and secondary prevention: about a 40% stroke reduction by oral anticoagulants versus antiplatelet therapy (<LINK REF="REF-Hart-2007" TYPE="REFERENCE">Hart 2007</LINK>).</P>
<P>For primary prevention of stroke in AF patients, the absolute risk reductions afforded by oral anticoagulants over antiplatelet therapy are modest. In early trials from the 1980s and early 1990s, the annualized rate of stroke during antiplatelet therapy was about 4% per year, but more recent trials report lower absolute stroke rates despite similar entry criteria and patient demographical data. It has been speculated that better control of hypertension and wider use of statin drugs may have resulted in declining stroke rates for AF patients independent of antithrombotic therapy (<LINK REF="REF-Arima-2005" TYPE="REFERENCE">Arima 2005</LINK>). Hence, the absolute benefits of oral anticoagulants over antiplatelet therapy in AF patients may be shifting. In the recent <LINK REF="STD-ACTIVE-W" TYPE="STUDY">ACTIVE W</LINK> trial (2002 to 2005) involving patients with high-risk AF (<I>see</I> participant description in the 'Characteristics of included studies' table), the observed stroke rate during treatment with aspirin plus clopidogrel was 2.4% per year with an absolute reduction by oral anticoagulants of 1.0% per year (about 100 patients would need to be treated for one year to prevent one stroke). On the other hand, oral anticoagulants offer larger absolute benefits for secondary prevention (<LINK REF="REF-Saxena-2006" TYPE="REFERENCE">Saxena 2006</LINK>). </P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Adjusted-dose warfarin and related oral anticoagulants reduce stroke and other major ischemic vascular events for those with non-valvular AF, and the effect is still significant (about 30%) when compared with the effect of aspirin (which reduces stroke by about 20% in AF patients) (<LINK REF="REF-Aguilar-2006a" TYPE="REFERENCE">Aguilar 2006a</LINK>). Adjusted-dose warfarin offers larger, more predictable reductions in stroke for AF patients who can safely receive it (<LINK REF="REF-Van-Walraven-2002" TYPE="REFERENCE">Van Walraven 2002</LINK>). Most guidelines recommend adjusted-dose warfarin for AF patients at high risk for stroke and aspirin for those deemed at low risk or for those who cannot safely receive adjusted-dose warfarin. Stroke risk stratification schemes have been developed and validated for AF patients that allow reliable classification of risk (<LINK REF="REF-Gage-2004" TYPE="REFERENCE">Gage 2004</LINK>; <LINK REF="REF-Go-2003" TYPE="REFERENCE">Go 2003</LINK>; <LINK REF="REF-Hart-2003" TYPE="REFERENCE">Hart 2003</LINK>). The threshold of benefit that would warrant anticoagulation remains controversial and depends on patient preferences and availability of optimal anticoagulation monitoring. In most cohorts of AF patients without prior stroke or TIA, about 40% have a sufficiently low stroke rate during antiplatelet therapy that the absolute benefits of oral anticoagulants would be small (below 1% per year) (<LINK REF="REF-Hart-2003" TYPE="REFERENCE">Hart 2003</LINK>). </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Antithrombotic agents that are more efficacious than aspirin and that are safer and easier to use than adjusted-dose warfarin are needed for the growing population of elderly patients with non-valvular AF. A substantial unmet need remains for those who are unable to receive oral anticoagulants, yet whose stroke risk remains increased.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS/>
<CONFLICT_OF_INTEREST>
<P>Dr Hart and Ms Pearce were leaders of the SPAF II trials that are included in this review (<LINK REF="STD-SPAF-IIa" TYPE="STUDY">SPAF IIa</LINK>; <LINK REF="STD-SPAF-IIb" TYPE="STUDY">SPAF IIb</LINK>). Dr Hart served on the Writing and Operations Committees of the <LINK REF="STD-ACTIVE-W" TYPE="STUDY">ACTIVE W</LINK> trial included in this review.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Drs Aguilar and Hart performed the systematic review, screened and appraised the quality of published papers, abstracted data from included studies, interpreted the analyses, and wrote the review.</P>
<P>Lesly Pearce assisted with global data analysis and interpretation.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-09-09 16:01:58 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-09-09 16:01:58 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2008-09-09 16:01:43 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-ACTIVE-W" NAME="ACTIVE W" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>ACTIVE Writing Group</AU>
<TI>Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2006</YR>
<VL>367</VL>
<PG>1903-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-AFASAK-I" NAME="AFASAK I" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B</AU>
<TI>Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study</TI>
<SO>Lancet</SO>
<YR>1989</YR>
<VL>1</VL>
<PG>175-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-AFASAK-II" NAME="AFASAK II" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gullov AL, Koefoed BG, Petersen P, Pedersen TS, Andersen ED, Godtfredsen J, et al</AU>
<TI>Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1998</YR>
<VL>158</VL>
<PG>1513-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ATHENS" NAME="ATHENS" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vemmos KN, Tsivgoulis G, Spengos K, Manios E, Xinos K, Vassilopoulou S, et al</AU>
<TI>Primary prevention of arterial thromboembolism in the oldest old with atrial fibrillation - a randomized pilot trial comparing adjusted dose and fixed low-dose coumadin with aspirin</TI>
<SO>European Journal of Internal Medicine</SO>
<YR>2005</YR>
<VL>17</VL>
<PG>48-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NASPEAF" NAME="NASPEAF" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perez-Gomez F, Alegria E, Berjon J, Iriarte JA, Zumalde J, Salvador A, et al</AU>
<TI>Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation</TI>
<SO>Journal of the American College of Cardiology</SO>
<YR>2004</YR>
<VL>44</VL>
<PG>1557-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PATAF" NAME="PATAF" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hellemons BSP, Langenberg M, Lodder J, Vermeer F, Schouten HJA, Lemmens Th, et al</AU>
<TI>Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin</TI>
<SO>BMJ</SO>
<YR>1999</YR>
<VL>319</VL>
<PG>958-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SPAF-IIa" MODIFIED="2008-09-09 16:01:43 +0100" MODIFIED_BY="[Empty name]" NAME="SPAF IIa" YEAR="1994">
<REFERENCE MODIFIED="2008-09-09 16:01:43 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Subjects 75 years of age and younger&lt;/p&gt;" NOTES_MODIFIED="2008-09-09 16:01:43 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stroke Prevention in Atrial Fibrillation Investigators</AU>
<TI>Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study</TI>
<SO>Lancet</SO>
<YR>1994</YR>
<VL>343</VL>
<PG>687-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SPAF-IIb" NAME="SPAF IIb" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Subjects older than 75 years&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stroke Prevention in Atrial Fibrillation Investigators</AU>
<TI>Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study</TI>
<SO>Lancet</SO>
<YR>1994</YR>
<VL>343</VL>
<PG>687-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-09-09 16:01:58 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-EAFT" NAME="EAFT" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>European Atrial Fibrillation Trial Study Group</AU>
<TI>Secondary prevention of vascular events in patients with nonrheumatic atrial fibrillation and recent transient ischemic attack or minor ischemic stroke</TI>
<SO>Lancet</SO>
<YR>1993</YR>
<VL>342</VL>
<PG>1255-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Japanese-AF" NAME="Japanese AF" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sato H, Ishikawa K, Kitabatake A, Ogawa S, Maruyama Y, Yokota Y, et el</AU>
<TI>Low-dose aspirin for prevention of stroke in patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial</TI>
<SO>Stroke</SO>
<YR>2006</YR>
<VL>37</VL>
<PG>447-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SIFA" NAME="SIFA" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morocutti C, Amabile G, Fattapposta F, Nicolosi A, Matteoli S, Trappolini M, et al</AU>
<TI>Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators</TI>
<SO>Stroke</SO>
<YR>1997</YR>
<VL>28</VL>
<PG>1015-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-TAFT" MODIFIED="2008-09-09 16:01:58 +0100" MODIFIED_BY="[Empty name]" NAME="TAFT" YEAR="2000">
<REFERENCE MODIFIED="2008-09-09 16:01:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yigit Z</AU>
<TI>The Turkish atrial fibrillation study</TI>
<SO>Turk Kardiyoloji Dernegi Arsivi</SO>
<YR>2000</YR>
<VL>28</VL>
<PG>8-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-09-09 16:00:51 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-09-09 16:00:51 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-AFI-1994" NAME="AFI 1994" TYPE="JOURNAL_ARTICLE">
<AU>Atrial Fibrillation Investigators</AU>
<TI>Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized clinical trials</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1994</YR>
<VL>154</VL>
<PG>1949-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Aguilar-2006a" MODIFIED="2008-09-09 15:59:28 +0100" MODIFIED_BY="[Empty name]" NAME="Aguilar 2006a" TYPE="COCHRANE_REVIEW">
<AU>Aguilar M, Hart R</AU>
<TI>Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-09-09 15:59:28 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-09 15:59:28 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="Art. No.: CD001925. DOI: 10.1002/14651858.CD001925"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Aguilar-2006b" MODIFIED="2008-09-09 16:00:02 +0100" MODIFIED_BY="[Empty name]" NAME="Aguilar 2006b" TYPE="COCHRANE_REVIEW">
<AU>Aguilar MI, Hart R</AU>
<TI>Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-09-09 16:00:02 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-09 16:00:02 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="Art. No.: CD006186. DOI: 10.1002/14651858.CD006186"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Arima-2005" NAME="Arima 2005" TYPE="JOURNAL_ARTICLE">
<AU>Arima H, Hart RG, Colman S, Chalmers J, Anderson C, Rodgers A, et al</AU>
<TI>Perindopril-based blood pressure-lowering reduces major vascular events in patients with atrial fibrillation and prior stroke or transient ischemic attack</TI>
<SO>Stroke</SO>
<YR>2005</YR>
<VL>36</VL>
<PG>2164-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CHARISMA-2006" NAME="CHARISMA 2006" TYPE="JOURNAL_ARTICLE">
<AU>Bhatt DL, Fox KA, Hacke W</AU>
<TI>Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events</TI>
<SO>New England Journal of Medicine</SO>
<YR>2006</YR>
<VL>354</VL>
<PG>1706-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CONSORT-2001" NAME="CONSORT 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Schulz KF, Altman DG</AU>
<TI>The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2001</YR>
<VL>1</VL>
<PG>2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Feinberg-1995" NAME="Feinberg 1995" TYPE="JOURNAL_ARTICLE">
<AU>Feinberg WM, Blackshear JL, Laupacis A, Kronmal RA, Hart RG</AU>
<TI>Prevalence, age distribution, and gender of patients with atrial fibrillation</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1995</YR>
<VL>155</VL>
<PG>469-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gage-2001" NAME="Gage 2001" TYPE="JOURNAL_ARTICLE">
<AU>Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ</AU>
<TI>Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>285</VL>
<PG>2864-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gage-2004" NAME="Gage 2004" TYPE="JOURNAL_ARTICLE">
<AU>Gage BF, van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BSP, et al</AU>
<TI>Selecting patients with atrial fibrillation for anticoagulation. Stroke risk stratification in patients taking aspirin</TI>
<SO>Circulation</SO>
<YR>2004</YR>
<VL>110</VL>
<PG>2287-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Go-2001" NAME="Go 2001" TYPE="JOURNAL_ARTICLE">
<AU>Go AS, Hylek EM, Phillips KA, Chang YC, Henault LE, Selby JV, et al</AU>
<TI>Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>285</VL>
<PG>2370-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Go-2003" NAME="Go 2003" TYPE="JOURNAL_ARTICLE">
<AU>Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, et al</AU>
<TI>Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>290</VL>
<PG>2685-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hart-1999" NAME="Hart 1999" TYPE="JOURNAL_ARTICLE">
<AU>Hart RG, Pearce L, McBride R, Rothbart RM, Asinger RW</AU>
<TI>Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials</TI>
<SO>Stroke</SO>
<YR>1999</YR>
<VL>30</VL>
<PG>1223-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hart-2003" NAME="Hart 2003" TYPE="JOURNAL_ARTICLE">
<AU>Hart RG, Halperin JL, Pearce LA, Anderson DC, Kronmal RA, McBride R, et al</AU>
<TI>Lessons from the stroke prevention in atrial fibrillation trials</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2003</YR>
<VL>138</VL>
<PG>831-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hart-2007" MODIFIED="2008-09-09 15:57:58 +0100" MODIFIED_BY="[Empty name]" NAME="Hart 2007" TYPE="OTHER">
<AU>Hart RG, Pearce LA, Aguilar MI</AU>
<TI>Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: an updated meta-analysis</TI>
<SO>Annals of Internal Medicine (accepted for publication)</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hylek-2003" NAME="Hylek 2003" TYPE="JOURNAL_ARTICLE">
<AU>Hylek EM, Go AS, Chang Y, Jensvold NG, Henaut LE, Selby JV, et al</AU>
<TI>Effect of oral anticoagulation on stroke severity and mortality in atrial fibrillation</TI>
<SO>New England Journal of Medicine</SO>
<YR>2003</YR>
<VL>349</VL>
<PG>1019-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Oden-2006" NAME="Oden 2006" TYPE="JOURNAL_ARTICLE">
<AU>Oden A, Fahlen M, Hart RG</AU>
<TI>Optimal INR for prevention of stroke and mortality in atrial fibrillation: a critical appraisal</TI>
<SO>Thrombosis Research</SO>
<YR>2006</YR>
<VL>117</VL>
<PG>493-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saxena-2006" MODIFIED="2008-09-09 16:00:51 +0100" MODIFIED_BY="[Empty name]" NAME="Saxena 2006" TYPE="COCHRANE_REVIEW">
<AU>Saxena R, Koudstaal PJ</AU>
<TI>Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-09-09 16:00:51 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-09 16:00:51 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="Art. No.: CD000187. DOI: 10.1002/14651858.CD000187"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Taylor-2001" NAME="Taylor 2001" TYPE="JOURNAL_ARTICLE">
<AU>Taylor FC, Cohen H, Ebrahim S</AU>
<TI>Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation</TI>
<SO>BMJ</SO>
<YR>2001</YR>
<VL>322</VL>
<PG>321-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-Walraven-2002" NAME="Van Walraven 2002" TYPE="JOURNAL_ARTICLE">
<AU>Van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, et al</AU>
<TI>Oral anticoagulants vs aspirin on nonvalvular atrial fibrillation. An individual patient meta-analysis</TI>
<SO>JAMA</SO>
<YR>2002</YR>
<VL>288</VL>
<PG>2441-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wang-2003" NAME="Wang 2003" TYPE="JOURNAL_ARTICLE">
<AU>Wang TJ, Massaro JM, Levy D, Vasan RS, Wolf PA, D'Agostino RB, et al</AU>
<TI>A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community. The Framingham Heart Study</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>290</VL>
<PG>1049-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wolf--1991" NAME="Wolf  1991" TYPE="JOURNAL_ARTICLE">
<AU>Wolf PA, Abbot RD, Kannel WB</AU>
<TI>Atrial fibrillation as an independent risk factor for stroke: The Framingham Study</TI>
<SO>Stroke</SO>
<YR>1991</YR>
<VL>22</VL>
<PG>983-8</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-ACTIVE-W">
<CHAR_METHODS>
<P>Automated central interactive voice response system randomization<BR/>Randomized to 2 groups: clopidogrel plus aspirin and OAC (warfarin)<BR/>Open treatment allocation<BR/>Blinded event adjudication<BR/>Losses to follow up: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Asia, Australia, Europe, North and South America, South Africa<BR/>Total number of patients: 6706<BR/>AF verified by ECG plus at least one of: (1) age equal or greater than 75; (2) on treatment of systemic hypertension; (3) history of prior stroke, TIA or non-CNS embolism; (4) left ventricular dysfunction with left ventricular ejection fraction &lt; 45%; (5) peripheral arterial disease; (6) if age 55 to 74, patients were required to have either DM requiring drug therapy or previous coronary artery disease<BR/>15% had history of stroke or TIA<BR/>Age range: 60 to 79 years; mean 70.2 years<BR/>66% male</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>APT: clopidogrel 75 mg/day plus aspirin 75 to 100 mg/day (3335 patients, mean age 70.2 years)<BR/>OAC: warfarin adjusted to INR 2.0 to 3.0 (3371 patients, mean age 70.2 years)<BR/>INR therapeutic &gt; 60%<BR/>Follow up: 1.25 years</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome: first occurrence of stroke, non-CNS embolism, MI or vascular death<BR/>Secondary outcome: major bleeding</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Stopped early due to evidence of superiority of oral anticoagulants</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-AFASAK-I">
<CHAR_METHODS>
<P>Computer-generated randomization<BR/>Randomized to 3 groups (warfarin, aspirin, placebo)<BR/>Primary stroke prevention trial<BR/>Double-blind: aspirin vs placebo<BR/>Open-label: warfarin<BR/>Intention-to-treat analysis<BR/>Exclusions during the trial: none<BR/>About 4% had a stroke, and 1.5% a TIA prior entry to the trial<BR/>Losses to follow up: not reported<BR/>Off therapy: 222 patients in the 3 groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Denmark<BR/>Total number of patients: 1007 <BR/>Chronic non-rheumatic AF (verified by ECG)<BR/>No cerebrovascular events within past month and no prior anticoagulation therapy during last 6 months<BR/>Older than 18 years<BR/>Age: range 38 to 91, median 74.2 years<BR/>54% male<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>OAC: warfarin, INR: 2.8 to 4.2 (335 patients, median age 72.8 years)<BR/>APT: aspirin 75 mg/day (336 patients)<BR/>INR therapeutic range: within target range 73% of the time, above target range 0.6% and below in 26% of the time<BR/>Follow up for a maximum of 2 years</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes: ischemic stroke and TIA, systemic emboli (extremities and viscera)<BR/>Secondary outcome: death<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Not all patients had CT in the antiaggregant group when they had an outcome<BR/>They did not define major or minor bleeding, but only 1 patient required transfusion<BR/>The incidence of MI was not reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-AFASAK-II">
<CHAR_METHODS>
<P>Computer-generated randomization<BR/>Randomized to 4 groups: fixed-dose warfarin, fixed-dose warfarin plus aspirin, aspirin alone, adjusted-dose warfarin<BR/>Open label<BR/>Intention-to-treat analysis<BR/>8% with prior stroke or TIA<BR/>Mean age 73 years<BR/>Losses to follow up: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Denmark<BR/>Total number of patients: 677<BR/>Non-valvular chronic AF documented by ECG<BR/>No TIA or stroke in the prior 6 months<BR/>Patients already on adjusted-dose warfarin were excluded<BR/>18 years and older<BR/>Age range: 44 to 89 years, median 74 years<BR/>60% male</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>APT: aspirin 300 mg/day (169 patients)<BR/>OAC: adjusted dose warfarin, (INR 2.0 to 3.0 (170 patients)<BR/>INR therapeutic range: within target 73% of the time, above target range 9% and below 18% of the time<BR/>Mean follow up 3.5 years</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome: stroke (ischemic or hemorrhagic) or systemic embolism</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Diagnosis of stroke was not conformed by neuroimaging</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-ATHENS">
<CHAR_METHODS>
<P>Central telephone randomization<BR/>Randomized to 3 groups: aspirin 100mg/day, fixed-dose coumarinic (acenocumarol), adjusted-dose coumarinic (accenocumarol)<BR/>Open label<BR/>Primary prevention in the elderly<BR/>Losses to follow up: not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Greece<BR/>Total number of participants: 45<BR/>Age over 75 years<BR/>Non-valvular chronic AF, confirmed by ECG</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>APT: aspirin 100 mg/day (15 patients)<BR/>OAC: acenocumarol adjusted to INR 1.6 to 2.5 (16 patients)<BR/>INR therapeutic: within range 84% of measurements, above range 14.1% and below range 37.2% of measurements</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome: arterial thromboembolism and bleeding<BR/>Secondary outcome: efficacy of anticoagulation monitoring in the elderly with AF</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Stopped 6 months after enrolment of the first patients due to safety concerns</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-NASPEAF">
<CHAR_METHODS>
<P>Computer-generated randomization<BR/>Randomization to 2 groups: intermediate and high risk (those with prior embolism or mitral stenosis). Only the intermediate risk group was considered for this analysis (primary prevention)<BR/>Three treatment arms within the intermediate risk group: triflusal, adjusted-dose acenocumarol, triflusal plus adjusted-dose acenocumarol<BR/>Open label<BR/>Intention-to-treat and 'on-treatment' analyses<BR/>50 patients lost to follow up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Spain<BR/>Total number of participants: 1209. High-risk group (secondary prevention) 495 patients, intermediate risk group (primary prevention) 714 patients<BR/>Chronic or paroxysmal AF documented by ECG<BR/>Age older than 60 years<BR/>Age range 61 to 77 years<BR/>Mean 69 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>APT: triflusal 600 mg/day (242 patients)<BR/>OAC: acenocumarol adjusted to INR 2 to 3 (237 patients)<BR/>Median INR 2.5<BR/>INR within range 65% of the time, above range 16% and below range 19% of the time<BR/>Median follow up: 2.76 years</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome: composite of vascular death, TIA and non-fatal stroke, or systemic embolism, whichever came first<BR/>Secondary outcomes: severe bleeding, MI, non-vascular death, non-severe bleeding</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Unknown prior history of TIA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-PATAF">
<CHAR_METHODS>
<P>Central telephone randomization<BR/>Randomization to 5 groups: patients eligible for anticoagulation randomized to aspirin 150 mg, low anticoagulation (INR 1.1 to 1.6) or standard anticoagulation (INR 2.5 to 3.5). Patients ineligible for anticoagulation were randomized to aspirin or low anticoagulation <BR/>Single blinded: patients were blinded to the intensity of anticoagulation<BR/>Intention-to-treat analysis<BR/>No losses to follow up<BR/>77 patients 'off' therapy</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>The Netherlands<BR/>871 patients eligible, 729 randomized<BR/>Non-rheumatic chronic or intermittent AF documented by ECG in the preceding 2 years<BR/>No history of stroke, treatable AF, MI or cardiovascular surgery in the preceding year, warfarin use in the preceding three months<BR/>For standard anticoagulation excluded if age equal or greater than 78 years <BR/>45% male<BR/>Mean age 75 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>APT: aspirin 150 mg/day<BR/>OAC: warfarin adjusted to INR 2.5 to 3.5<BR/>INR within range: 48% of measurements within target INR (2.5 to 3.5) <BR/>Low-intensity anticoagulation arm: 75% within target (1.1 to 1.6)<BR/>Mean follow up: 2.7 years</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome: stroke (non-disabling, minor disabling, major disabling, ischemic, hemorrhagic), systemic arterial embolism, major hemorrhage, vascular death<BR/>Secondary outcomes: non-fatal MI, retinal infarction, TIA, minor bleeding complication, non-vascular death</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Unknown prior history of TIA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-SPAF-IIa">
<CHAR_METHODS>
<P>Computer generated randomization<BR/>Two groups: age 75 years and younger (SPAF IIa for this analysis), and older than 75 years (SPAF IIb for this analysis)<BR/>Within each group 2 treatment arms: aspirin 325 mg/day or adjusted-dose warfarin (INR 2.0 to 4.5)<BR/>4 patients were lost to follow up<BR/>Intention-to-treat analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>USA<BR/>715 patients aged 75 years or less, 385 patients aged older than 75 years<BR/>Age older than 60 years<BR/>Mean age 64 years<BR/>Those with history of stroke or TIA more than 2 years prior to entry were eligible<BR/>Those with lone AF were excluded (that is those without overt cardiovascular disease)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>APT: aspirin 325 mg/day<BR/>OAC: warfarin adjusted to prothrombin time ratio 1.3 to 1.8. During second half of the study adjusted to INR 2.0 to 4.5 (available for 86% of the measures)<BR/>Mean INR achieved for those 75 years and under: 2.7; for those older than 75 years: 2.6<BR/>INR within therapeutic range 75% of the measurements for those 75 years and under. INR above range in 5% and below range 20% of the measurements<BR/>Mean follow up: 3.1 years</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome: ischemic stroke and systemic embolism<BR/>Secondary outcomes: all disabling strokes (with residual functional deficit), vascular death</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Neuroimaging or necropsy confirmation of stroke in 98% of events</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-SPAF-IIb">
<CHAR_METHODS>
<P>Two groups: age 75 years and younger (SPAF IIa for this analysis), and older than 75 years (SPAF IIb for this analysis)<BR/>Within each group 2 treatment arms: aspirin 325 mg/day or adjusted-dose warfarin (INR 2.0 to 4.5)<BR/>4 patients were lost to follow up<BR/>Intention-to-treat analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>USA<BR/>715 patients aged 75 years or less<BR/>385 patients aged older than 75 years<BR/>Age older than 60 years<BR/>Those with history of stroke or TIA more than 2 years prior to entry were eligible<BR/>Those with lone AF were excluded (that is those without overt cardiovascular disease)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>APT: aspirin 325 mg/day<BR/>OAC: warfarin adjusted to prothrombin time ratio 1.3 to 1.8. During second half of the study adjusted to INR 2.0 to 4.5 (available for 86% of the measures)<BR/>Mean INR achieved for those older than 75 years: 2.6<BR/>INR within therapeutic range 72% of the measurements for those older than 75 years. INR above range in 6% and below range 22% of the measurements<BR/>Mean follow up: 3.1 years</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcome: ischemic stroke and systemic embolism<BR/>Secondary outcomes: all disabling strokes (with residual functional deficit), vascular death</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Neuroimaging or necropsy confirmation of stroke in 98% of events</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AF: atrial fibrillation<BR/>APT: antiplatelet therapy<BR/>CNS: central nervous system<BR/>CT: computerized tomography<BR/>DM: diabetes mellitus<BR/>ECG: electrocardiogram<BR/>INR: international normalized ratio<BR/>MI: myocardial infarction<BR/>OAC: oral anticoagulants<BR/>TIA: transient ischemic attack<BR/>vs: versus</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-EAFT">
<CHAR_REASON_FOR_EXCLUSION>
<P>Secondary prevention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Japanese-AF">
<CHAR_REASON_FOR_EXCLUSION>
<P>Aspirin or control; no anticoagulation arm</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-SIFA">
<CHAR_REASON_FOR_EXCLUSION>
<P>Secondary prevention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-TAFT">
<CHAR_REASON_FOR_EXCLUSION>
<P>51% of randomized patients were excluded from the available published results</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-ACTIVE-W">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-AFASAK-I">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-AFASAK-II">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-ATHENS">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-NASPEAF">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-PATAF">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-SPAF-IIa">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-SPAF-IIb">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES>
<ADDITIONAL_TABLE ID="TBL-01" NO="1">
<TITLE>Study quality assessment</TITLE>
<TABLE COLS="9" ROWS="14">
<TR>
<TH>
<P/>
</TH>
<TH>
<P>ACTIVE W</P>
</TH>
<TH>
<P>AFASAK I</P>
</TH>
<TH>
<P>AFASAK II</P>
</TH>
<TH>
<P>ATHENS</P>
</TH>
<TH>
<P>NASPEAF</P>
</TH>
<TH>
<P>PATAF</P>
</TH>
<TH>
<P>SPAF II A</P>
</TH>
<TH>
<P>SPAF II B</P>
</TH>
</TR>
<TR>
<TD>
<P>Eligibility criteria</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>Intervention</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>Primary and secondary outcomes</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>Randomization method</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>Allocation blocked from pre-viewing</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinician blinded</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>Patient blinded</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>Intention to treat</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>Withdrawal rate</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>Lost to follow up</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>Baseline features balanced</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>Fraction of strokes with confirmation</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>TOTAL SCORE</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>8</P>
</TD>
<TD>
<P>7</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>10</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Oral anticoagulant versus antiplatelet</NAME>
<DICH_OUTCOME CHI2="3.7946468647339024" CI_END="0.8492875574762905" CI_START="0.5434634136368784" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6793796546448764" ESTIMABLE="YES" EVENTS_1="132" EVENTS_2="190" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.0709452385185214" LOG_CI_START="-0.26482968762265974" LOG_EFFECT_SIZE="-0.16788746307059055" METHOD="PETO" NO="1" P_CHI2="0.8031030557135246" P_Q="1.0" P_Z="6.879808560031764E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4815" TOTAL_2="4783" WEIGHT="99.99999999999999" Z="3.3943246360868917">
<NAME>All strokes (ischemic and hemorrhagic): primary outcome</NAME>
<GROUP_LABEL_1>Oral anticoagulant</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiplatelet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OAC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours APT</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8078232840916955" CI_START="0.43936080339397154" EFFECT_SIZE="0.5957565669792351" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="106" LOG_CI_END="-0.09268363320761816" LOG_CI_START="-0.3571786903126724" LOG_EFFECT_SIZE="-0.2249311617601453" ORDER="76578" O_E="-21.456307784073957" SE="0.15536570581515718" STUDY_ID="STD-ACTIVE-W" TOTAL_1="3371" TOTAL_2="3335" VAR="41.42759055580619" WEIGHT="53.73420567921048"/>
<DICH_DATA CI_END="1.2469517820057168" CI_START="0.2525536065576325" EFFECT_SIZE="0.561179267034172" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="16" LOG_CI_END="0.09584966020370919" LOG_CI_START="-0.5976464252237177" LOG_EFFECT_SIZE="-0.25089838251000424" ORDER="76579" O_E="-3.4813710879284656" SE="0.4073630334410579" STUDY_ID="STD-AFASAK-I" TOTAL_1="335" TOTAL_2="336" VAR="6.026106018776611" WEIGHT="7.8162407205766895"/>
<DICH_DATA CI_END="2.798818435504132" CI_START="0.44074437502911396" EFFECT_SIZE="1.1106590305652906" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.44697472589872345" LOG_CI_START="-0.35581322164782414" LOG_EFFECT_SIZE="0.045580752125449625" ORDER="76580" O_E="0.47197640117994055" SE="0.47156161425327203" STUDY_ID="STD-AFASAK-II" TOTAL_1="170" TOTAL_2="169" VAR="4.497002288528641" WEIGHT="5.8328964506436005"/>
<DICH_DATA CI_END="4.756911562842407" CI_START="0.04380308600800488" EFFECT_SIZE="0.4564727881480547" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6773250773970805" LOG_CI_START="-1.3584952915727164" LOG_EFFECT_SIZE="-0.340585107087818" ORDER="76581" O_E="-0.5483870967741935" SE="1.1958509622062123" STUDY_ID="STD-ATHENS" TOTAL_1="16" TOTAL_2="15" VAR="0.6992715920915713" WEIGHT="0.9069994911835696"/>
<DICH_DATA CI_END="1.4623229887739253" CI_START="0.21136502041714939" EFFECT_SIZE="0.5559531710303195" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.16504330747126925" LOG_CI_START="-0.6749668840900206" LOG_EFFECT_SIZE="-0.2549617883093756" ORDER="76582" O_E="-2.411273486430062" SE="0.4934261446406111" STUDY_ID="STD-NASPEAF" TOTAL_1="237" TOTAL_2="242" VAR="4.107293004414823" WEIGHT="5.327418855960389"/>
<DICH_DATA CI_END="3.6038518421491483" CI_START="0.17968162811486332" EFFECT_SIZE="0.8047024086468914" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5567669284058926" LOG_CI_START="-0.7454963258750397" LOG_EFFECT_SIZE="-0.0943646987345735" ORDER="76583" O_E="-0.3713235294117645" SE="0.764955881871693" STUDY_ID="STD-PATAF" TOTAL_1="131" TOTAL_2="141" VAR="1.7089416062034757" WEIGHT="2.216605371673682"/>
<DICH_DATA CI_END="1.6967465407130955" CI_START="0.4741714865726388" EFFECT_SIZE="0.8969664595440071" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="21" LOG_CI_END="0.22961697243504084" LOG_CI_START="-0.32406456506992853" LOG_EFFECT_SIZE="-0.04722379631744384" ORDER="76584" O_E="-1.0279720279720266" SE="0.3252352758982322" STUDY_ID="STD-SPAF-IIa" TOTAL_1="358" TOTAL_2="357" VAR="9.453763020196586" WEIGHT="12.26212868656831"/>
<DICH_DATA CI_END="1.716487349550209" CI_START="0.4706308749105528" EFFECT_SIZE="0.8987947168801732" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="21" LOG_CI_END="0.23464060703891249" LOG_CI_START="-0.32731958509998427" LOG_EFFECT_SIZE="-0.046339489030535905" ORDER="76585" O_E="-0.9792207792207783" SE="0.3300981986102025" STUDY_ID="STD-SPAF-IIb" TOTAL_1="197" TOTAL_2="188" VAR="9.177273851689435" WEIGHT="11.903504744183254"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.264047157791186" CI_END="0.6776915390342697" CI_START="0.4136908148782705" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.5294853775310479" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="170" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.16896793648431643" LOG_CI_START="-0.3833241215796306" LOG_EFFECT_SIZE="-0.2761460290319735" METHOD="PETO" NO="2" P_CHI2="0.5092785855600425" P_Q="1.0" P_Z="4.420927534709971E-7" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4815" TOTAL_2="4783" WEIGHT="100.0" Z="5.049877810950571">
<NAME>Ischemic strokes (fatal and non-fatal)</NAME>
<GROUP_LABEL_1>Oral anticoagulant</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiplatelet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OAC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours APT</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6488427495324356" CI_START="0.32979738649601076" EFFECT_SIZE="0.4625869032329849" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="94" LOG_CI_END="-0.18786054400896413" LOG_CI_START="-0.48175279027687984" LOG_EFFECT_SIZE="-0.334806667142922" ORDER="76586" O_E="-25.867730390694902" SE="0.17263376024785526" STUDY_ID="STD-ACTIVE-W" TOTAL_1="3371" TOTAL_2="3335" VAR="33.55432752850227" WEIGHT="53.19805841679983"/>
<DICH_DATA CI_END="1.1353830630452024" CI_START="0.2227886839157386" EFFECT_SIZE="0.5029418439104671" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="0.055142411396464745" LOG_CI_START="-0.652106872016085" LOG_EFFECT_SIZE="-0.29848223030981014" ORDER="76587" O_E="-3.9821162444113263" SE="0.41544173001694706" STUDY_ID="STD-AFASAK-I" TOTAL_1="335" TOTAL_2="336" VAR="5.794016982016299" WEIGHT="9.186011956741233"/>
<DICH_DATA CI_END="2.978326401913084" CI_START="0.42453558167872385" EFFECT_SIZE="1.1244578833665901" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.4739722913952847" LOG_CI_START="-0.3720859042913382" LOG_EFFECT_SIZE="0.05094319355197328" ORDER="76588" O_E="0.47492625368731645" SE="0.496978772201935" STUDY_ID="STD-AFASAK-II" TOTAL_1="170" TOTAL_2="169" VAR="4.048781336744372" WEIGHT="6.41906191939082"/>
<DICH_DATA CI_END="1.9792724371207004" CI_START="0.007022813272580673" EFFECT_SIZE="0.11789851882642269" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.2965055768212881" LOG_CI_START="-2.1534888787524338" LOG_EFFECT_SIZE="-0.928491650965573" ORDER="76589" O_E="-1.032258064516129" SE="1.439138870872152" STUDY_ID="STD-ATHENS" TOTAL_1="16" TOTAL_2="15" VAR="0.4828303850156087" WEIGHT="0.7654940783911698"/>
<DICH_DATA CI_END="0.9192377710622487" CI_START="0.08430897318085218" EFFECT_SIZE="0.2783882048279227" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="-0.03657213899025208" LOG_CI_START="-1.0741262000426508" LOG_EFFECT_SIZE="-0.5553491695164514" ORDER="76590" O_E="-3.44258872651357" SE="0.6094643914376132" STUDY_ID="STD-NASPEAF" TOTAL_1="237" TOTAL_2="242" VAR="2.692175246591228" WEIGHT="4.268257079947962"/>
<DICH_DATA CI_END="3.6038518421491483" CI_START="0.17968162811486332" EFFECT_SIZE="0.8047024086468914" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5567669284058926" LOG_CI_START="-0.7454963258750397" LOG_EFFECT_SIZE="-0.0943646987345735" ORDER="76591" O_E="-0.3713235294117645" SE="0.764955881871693" STUDY_ID="STD-PATAF" TOTAL_1="131" TOTAL_2="141" VAR="1.7089416062034757" WEIGHT="2.709408356358444"/>
<DICH_DATA CI_END="1.3682855300693255" CI_START="0.33172486173133975" EFFECT_SIZE="0.673716801238651" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="19" LOG_CI_END="0.13617673422196608" LOG_CI_START="-0.47922197826011054" LOG_EFFECT_SIZE="-0.17152262201907223" ORDER="76592" O_E="-3.022377622377622" SE="0.3614882499847282" STUDY_ID="STD-SPAF-IIa" TOTAL_1="358" TOTAL_2="357" VAR="7.652646095163578" WEIGHT="12.132739470573402"/>
<DICH_DATA CI_END="1.3946081161648918" CI_START="0.32164130662790946" EFFECT_SIZE="0.6697488907920364" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="18" LOG_CI_END="0.14445218832865145" LOG_CI_START="-0.49262818228490884" LOG_EFFECT_SIZE="-0.17408799697812874" ORDER="76593" O_E="-2.862337662337662" SE="0.3742241632971004" STUDY_ID="STD-SPAF-IIb" TOTAL_1="197" TOTAL_2="188" VAR="7.140627002867261" WEIGHT="11.320968721797138"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.237522120674778" CI_END="1.042372767426087" CI_START="0.5914516331462178" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.7851834662302193" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="110" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.018023056665512502" LOG_CI_START="-0.22808076467351113" LOG_EFFECT_SIZE="-0.10502885400399929" METHOD="PETO" NO="3" P_CHI2="0.7784991016437979" P_Q="1.0" P_Z="0.09434821616748586" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4799" TOTAL_2="4763" WEIGHT="100.0" Z="1.6728937410669367">
<NAME>All disabling or fatal strokes (ischemic and hemorrhagic)</NAME>
<GROUP_LABEL_1>Oral anticoagulant</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiplatelet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OAC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours APT</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0554016716811354" CI_START="0.47143616304878344" EFFECT_SIZE="0.7053754422806526" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="56" LOG_CI_END="0.023417777733200442" LOG_CI_START="-0.3265771065589318" LOG_EFFECT_SIZE="-0.1515796644128657" ORDER="76594" O_E="-8.257679689830006" SE="0.20558872753581714" STUDY_ID="STD-ACTIVE-W" TOTAL_1="3371" TOTAL_2="3335" VAR="23.659273402595915" WEIGHT="49.443968531446664"/>
<DICH_DATA CI_END="2.1589701432234385" CI_START="0.2602041473707138" EFFECT_SIZE="0.7495151668353901" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.33424663644124025" LOG_CI_START="-0.5846857855382261" LOG_EFFECT_SIZE="-0.12521957454849295" ORDER="76595" O_E="-0.98956780923994" SE="0.5397854534595893" STUDY_ID="STD-AFASAK-I" TOTAL_1="335" TOTAL_2="336" VAR="3.432081929455559" WEIGHT="7.172483618990947"/>
<DICH_DATA CI_END="1.8842213432048456" CI_START="0.13381879561223878" EFFECT_SIZE="0.5021396527008669" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.2751319188847085" LOG_CI_START="-0.8734828831497023" LOG_EFFECT_SIZE="-0.2991754821324969" ORDER="76596" O_E="-1.5132743362831862" SE="0.6747020204499813" STUDY_ID="STD-AFASAK-II" TOTAL_1="170" TOTAL_2="169" VAR="2.1967264468634973" WEIGHT="4.590794969172556"/>
<DICH_DATA CI_END="19.542512436425806" CI_START="0.38295941554761154" EFFECT_SIZE="2.735688056227456" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.2909803970047156" LOG_CI_START="-0.41684724832285147" LOG_EFFECT_SIZE="0.4370665743409321" ORDER="76597" O_E="1.0" SE="1.0031864127485999" STUDY_ID="STD-NASPEAF" TOTAL_1="237" TOTAL_2="237" VAR="0.9936575052854123" WEIGHT="2.0765798503760093"/>
<DICH_DATA CI_END="5.426964750160403" CI_START="0.2140909977622623" EFFECT_SIZE="1.0778980926703912" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7345570007096508" LOG_CI_START="-0.6694015938189213" LOG_EFFECT_SIZE="0.03257770344536475" ORDER="76598" O_E="0.11029411764705888" SE="0.8246922281332095" STUDY_ID="STD-PATAF" TOTAL_1="131" TOTAL_2="141" VAR="1.4703346649599713" WEIGHT="3.072756279024164"/>
<DICH_DATA CI_END="1.4564681781003848" CI_START="0.3746025206816469" EFFECT_SIZE="0.7386451453905386" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="20" LOG_CI_END="0.16330100030842992" LOG_CI_START="-0.42642930460507744" LOG_EFFECT_SIZE="-0.1315641521483238" ORDER="76599" O_E="-2.5244755244755233" SE="0.34641050031828396" STUDY_ID="STD-SPAF-IIa" TOTAL_1="358" TOTAL_2="357" VAR="8.333317032617732" WEIGHT="17.415254395687025"/>
<DICH_DATA CI_END="2.1835413383743156" CI_START="0.5348627386857606" EFFECT_SIZE="1.080691861853534" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="16" LOG_CI_END="0.3391614183127349" LOG_CI_START="-0.2717576562587013" LOG_EFFECT_SIZE="0.03370188102701682" ORDER="76600" O_E="0.6025974025974037" SE="0.35885688850145275" STUDY_ID="STD-SPAF-IIb" TOTAL_1="197" TOTAL_2="188" VAR="7.7652854612919535" WEIGHT="16.228162355302622"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.271350779339587" CI_END="1.0132414815326738" CI_START="0.4718449152008741" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.6914425796346306" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="63" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.005712961252708961" LOG_CI_START="-0.3262007207300977" LOG_EFFECT_SIZE="-0.16024387973869436" METHOD="PETO" NO="4" P_CHI2="0.9378518742687727" P_Q="1.0" P_Z="0.05842526675904321" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4480" TOTAL_2="4447" WEIGHT="99.99999999999999" Z="1.8924934407921021">
<NAME>Myocardial infarction (fatal and non-fatal)</NAME>
<GROUP_LABEL_1>Oral anticoagulant</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiplatelet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OAC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours APT</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0588607245299242" CI_START="0.37986973713123195" EFFECT_SIZE="0.6342153775223115" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="36" LOG_CI_END="0.024838839667500428" LOG_CI_START="-0.42036530376148523" LOG_EFFECT_SIZE="-0.1977632320469924" ORDER="76601" O_E="-6.658365642708024" SE="0.2615151176462385" STUDY_ID="STD-ACTIVE-W" TOTAL_1="3371" TOTAL_2="3335" VAR="14.621987248039977" WEIGHT="55.58171140900069"/>
<DICH_DATA CI_END="4.032809562277893" CI_START="0.24499625748227047" EFFECT_SIZE="0.9939935864465109" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6056077141959144" LOG_CI_START="-0.6108405497873557" LOG_EFFECT_SIZE="-0.0026164177957206055" ORDER="76602" O_E="-0.011799410029498247" SE="0.7145477317797934" STUDY_ID="STD-AFASAK-II" TOTAL_1="170" TOTAL_2="169" VAR="1.9585628388197107" WEIGHT="7.444971236605518"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="76603" O_E="0.0" SE="0.0" STUDY_ID="STD-ATHENS" TOTAL_1="16" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.96433901755741" CI_START="0.0027408686367449177" EFFECT_SIZE="0.13816055294070742" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8428799040120367" LOG_CI_START="-2.5621117786538354" LOG_EFFECT_SIZE="-0.8596159373208994" ORDER="76604" O_E="-0.49478079331941544" SE="2.000108969378596" STUDY_ID="STD-NASPEAF" TOTAL_1="237" TOTAL_2="242" VAR="0.24997275988162532" WEIGHT="0.9502069427474267"/>
<DICH_DATA CI_END="4.201797732556695" CI_START="0.12256270409303444" EFFECT_SIZE="0.7176236424158066" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6234351423705563" LOG_CI_START="-0.9116416657946285" LOG_EFFECT_SIZE="-0.14410326171203602" ORDER="76605" O_E="-0.40808823529411775" SE="0.901711715868981" STUDY_ID="STD-PATAF" TOTAL_1="131" TOTAL_2="141" VAR="1.2298851990736603" WEIGHT="4.675091219921344"/>
<DICH_DATA CI_END="1.593672261785677" CI_START="0.3132731905454548" EFFECT_SIZE="0.7065796445790031" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" LOG_CI_END="0.20239901371470437" LOG_CI_START="-0.5040767698050532" LOG_EFFECT_SIZE="-0.1508388780451744" ORDER="76606" O_E="-2.0167832167832174" SE="0.4149873723510347" STUDY_ID="STD-SPAF-IIa" TOTAL_1="358" TOTAL_2="357" VAR="5.806711330627415" WEIGHT="22.07271473701842"/>
<DICH_DATA CI_END="3.342831916394594" CI_START="0.27181833295172136" EFFECT_SIZE="0.9532276741955128" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5241145400333327" LOG_CI_START="-0.5657212553619279" LOG_EFFECT_SIZE="-0.02080335766429752" ORDER="76607" O_E="-0.11688311688311703" SE="0.640174940989369" STUDY_ID="STD-SPAF-IIb" TOTAL_1="197" TOTAL_2="188" VAR="2.4400721032214534" WEIGHT="9.27530445470659"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.9147656862009494" CI_END="0.8997959411217" CI_START="0.251666806626035" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.4758663374490426" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-0.04585597021960085" LOG_CI_START="-0.599174061566377" LOG_EFFECT_SIZE="-0.3225150158929889" METHOD="PETO" NO="5" P_CHI2="0.5547907847006157" P_Q="1.0" P_Z="0.02232302507178542" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4815" TOTAL_2="4783" WEIGHT="100.0" Z="2.284826126270503">
<NAME>Systemic (non-CNS) emboli</NAME>
<GROUP_LABEL_1>Oral anticoagulant</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiplatelet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OAC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours APT</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7216293995569321" CI_START="0.14034120810623923" EFFECT_SIZE="0.31823629858770014" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="18" LOG_CI_END="-0.14168578172269222" LOG_CI_START="-0.8528147892322072" LOG_EFFECT_SIZE="-0.49725028547744976" ORDER="76608" O_E="-6.561735759021772" SE="0.4177206991564485" STUDY_ID="STD-ACTIVE-W" TOTAL_1="3371" TOTAL_2="3335" VAR="5.730968317321633" WEIGHT="60.54146862575514"/>
<DICH_DATA CI_END="2.619184454922462" CI_START="0.05151537977524617" EFFECT_SIZE="0.36732585247536254" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.41816608450165144" LOG_CI_START="-1.2880630941748856" LOG_EFFECT_SIZE="-0.434948504836617" ORDER="76609" O_E="-0.9970193740685545" SE="1.0022474655252471" STUDY_ID="STD-AFASAK-I" TOTAL_1="335" TOTAL_2="336" VAR="0.9955201769718884" WEIGHT="10.516591651411725"/>
<DICH_DATA CI_END="18.814218032085897" CI_START="0.20084916056498905" EFFECT_SIZE="1.9439186964559843" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2744861726209407" LOG_CI_START="-0.6971299790319114" LOG_EFFECT_SIZE="0.2886780967945146" ORDER="76610" O_E="0.49557522123893816" SE="1.1581370871382377" STUDY_ID="STD-AFASAK-II" TOTAL_1="170" TOTAL_2="169" VAR="0.7455556425718536" WEIGHT="7.875987275499957"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="76611" O_E="0.0" SE="0.0" STUDY_ID="STD-ATHENS" TOTAL_1="16" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="16.37548892330181" CI_START="0.06367648784559912" EFFECT_SIZE="1.021143291311445" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.214194275596471" LOG_CI_START="-1.1960208986519871" LOG_EFFECT_SIZE="0.009086688472241956" ORDER="76612" O_E="0.01043841336116913" SE="1.4157723241110736" STUDY_ID="STD-NASPEAF" TOTAL_1="237" TOTAL_2="242" VAR="0.4988996086340388" WEIGHT="5.270333620974381"/>
<DICH_DATA CI_END="17.334801562823834" CI_START="0.06687615059866903" EFFECT_SIZE="1.0767008869288863" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2389188745090651" LOG_CI_START="-1.174728732905606" LOG_EFFECT_SIZE="0.03209507080172974" ORDER="76613" O_E="0.03676470588235292" SE="1.4177885523437253" STUDY_ID="STD-PATAF" TOTAL_1="131" TOTAL_2="141" VAR="0.4974816535578851" WEIGHT="5.255354462479258"/>
<DICH_DATA CI_END="4.928350599852754" CI_START="0.05298768417587488" EFFECT_SIZE="0.5110204351031192" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6927015956996543" LOG_CI_START="-1.2758250608898296" LOG_EFFECT_SIZE="-0.29156173259508766" ORDER="76614" O_E="-0.5020979020979022" SE="1.156322302444768" STUDY_ID="STD-SPAF-IIa" TOTAL_1="358" TOTAL_2="357" VAR="0.7478976967088856" WEIGHT="7.900728538966445"/>
<DICH_DATA CI_END="356.13653541203405" CI_START="0.13991995888217645" EFFECT_SIZE="7.05907992526594" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5516165294561195" LOG_CI_START="-0.8541203311540689" LOG_EFFECT_SIZE="0.8487480991510253" ORDER="76615" O_E="0.48831168831168836" SE="2.000546690591778" STUDY_ID="STD-SPAF-IIb" TOTAL_1="197" TOTAL_2="188" VAR="0.24986338336987685" WEIGHT="2.6395358249131053"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.118497776162528" CI_END="3.282811814651774" CI_START="1.1976640469840572" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.982852915226674" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.5162459877549975" LOG_CI_START="0.07833501254208759" LOG_EFFECT_SIZE="0.2972905001485425" METHOD="PETO" NO="6" P_CHI2="0.9807189385514885" P_Q="1.0" P_Z="0.007786868150177282" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4810" TOTAL_2="4776" WEIGHT="100.0" Z="2.6611741025844258">
<NAME>All intracranial hemorrhages</NAME>
<GROUP_LABEL_1>Oral anticoagulant</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiplatelet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OAC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours APT</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.7124933635366455" CI_START="0.9254871035912169" EFFECT_SIZE="1.8536085698229667" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="11" LOG_CI_END="0.5696656859799515" LOG_CI_START="-0.03362962864332318" LOG_EFFECT_SIZE="0.26801802866831415" ORDER="76616" O_E="4.914106770056666" SE="0.35437865416968234" STUDY_ID="STD-ACTIVE-W" TOTAL_1="3371" TOTAL_2="3335" VAR="7.962783191574641" WEIGHT="52.68800503555471"/>
<DICH_DATA CI_END="373.49977301871183" CI_START="0.14705520071777145" EFFECT_SIZE="7.411145936311655" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.5722903422243735" LOG_CI_START="-0.8325196117343324" LOG_EFFECT_SIZE="0.8698853652450207" ORDER="76617" O_E="0.5007451564828613" SE="2.000002221036435" STUDY_ID="STD-AFASAK-I" TOTAL_1="335" TOTAL_2="336" VAR="0.24999944474181607" WEIGHT="1.6541919686297433"/>
<DICH_DATA CI_END="15.958823778378779" CI_START="0.061924064091333324" EFFECT_SIZE="0.9941002094731809" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.203000879158571" LOG_CI_START="-1.2081405485377017" LOG_EFFECT_SIZE="-0.002569834689565328" ORDER="76618" O_E="-0.002949852507374562" SE="1.4163164099713483" STUDY_ID="STD-AFASAK-II" TOTAL_1="170" TOTAL_2="169" VAR="0.49851637211649735" WEIGHT="3.298574442184003"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="76619" O_E="0.0" SE="0.0" STUDY_ID="STD-ATHENS" TOTAL_1="16" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="9.933422798094082" CI_START="0.3976913256273976" EFFECT_SIZE="1.9875703963863642" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9970989208207152" LOG_CI_START="-0.40045388166486195" LOG_EFFECT_SIZE="0.2983225195779266" ORDER="76620" O_E="1.0192719486081372" SE="0.8209294341779725" STUDY_ID="STD-NASPEAF" TOTAL_1="232" TOTAL_2="235" VAR="1.4838443422426844" WEIGHT="9.81827538124916"/>
<DICH_DATA CI_END="17.334801562823834" CI_START="0.06687615059866903" EFFECT_SIZE="1.0767008869288863" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2389188745090651" LOG_CI_START="-1.174728732905606" LOG_EFFECT_SIZE="0.03209507080172974" ORDER="76621" O_E="0.03676470588235292" SE="1.4177885523437253" STUDY_ID="STD-PATAF" TOTAL_1="131" TOTAL_2="141" VAR="0.4974816535578851" WEIGHT="3.291727934459891"/>
<DICH_DATA CI_END="11.021272399406175" CI_START="0.6799941148451385" EFFECT_SIZE="2.737590248686125" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.042231736452355" LOG_CI_START="-0.16749484597220737" LOG_EFFECT_SIZE="0.43736844524007384" ORDER="76622" O_E="1.9944055944055945" SE="0.7105993827593481" STUDY_ID="STD-SPAF-IIa" TOTAL_1="358" TOTAL_2="357" VAR="1.9803882830456259" WEIGHT="13.103798674295902"/>
<DICH_DATA CI_END="7.587227466887591" CI_START="0.6169462220521211" EFFECT_SIZE="2.163541384292518" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.8800831045113117" LOG_CI_START="-0.20975269088394882" LOG_EFFECT_SIZE="0.3351652068136815" ORDER="76623" O_E="1.883116883116883" SE="0.640174940989369" STUDY_ID="STD-SPAF-IIb" TOTAL_1="197" TOTAL_2="188" VAR="2.4400721032214534" WEIGHT="16.145426563626586"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.50996177836013" CI_END="1.2768590753415383" CI_START="0.7366126149073906" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.9698198298424112" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="105" I2="55.588327351076394" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.1061429676010568" LOG_CI_START="-0.13276084787893744" LOG_EFFECT_SIZE="-0.0133089401389403" METHOD="PETO" NO="7" P_CHI2="0.03561584587671729" P_Q="1.0" P_Z="0.8271386842334697" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4810" TOTAL_2="4776" WEIGHT="100.0" Z="0.21837276472385933">
<NAME>Major extracranial hemorrhage</NAME>
<GROUP_LABEL_1>Oral anticoagulant</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiplatelet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OAC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours APT</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0890906549238815" CI_START="0.5827250801453864" EFFECT_SIZE="0.7966432320531633" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="89" LOG_CI_END="0.03706403154140685" LOG_CI_START="-0.23453628972802912" LOG_EFFECT_SIZE="-0.0987361290933111" ORDER="76624" O_E="-8.932150313152405" SE="0.15953937315693983" STUDY_ID="STD-ACTIVE-W" TOTAL_1="3371" TOTAL_2="3335" VAR="39.288390462081495" WEIGHT="77.37231887407108"/>
<DICH_DATA CI_END="16.06859343603353" CI_START="0.0626058551320218" EFFECT_SIZE="1.0029895477180566" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2059778624693658" LOG_CI_START="-1.2033850480576898" LOG_EFFECT_SIZE="0.0012964072058379557" ORDER="76625" O_E="0.0014903129657227732" SE="1.4152717001823483" STUDY_ID="STD-AFASAK-I" TOTAL_1="335" TOTAL_2="336" VAR="0.49925262248440283" WEIGHT="0.983199684468136"/>
<DICH_DATA CI_END="2.5335197232549773" CI_START="0.10076629610573656" EFFECT_SIZE="0.5052656713286929" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4037242895887819" LOG_CI_START="-0.9966847046261629" LOG_EFFECT_SIZE="-0.29648020751869053" ORDER="76626" O_E="-1.0088495575221237" SE="0.82260717533818" STUDY_ID="STD-AFASAK-II" TOTAL_1="170" TOTAL_2="169" VAR="1.4777977915263527" WEIGHT="2.910290816513058"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="76627" O_E="0.0" SE="0.0" STUDY_ID="STD-ATHENS" TOTAL_1="16" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="38.23515510539339" CI_START="1.5307703928952439" EFFECT_SIZE="7.650440732604471" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="1.5824628562950502" LOG_CI_START="0.18491005380947295" LOG_EFFECT_SIZE="0.8836864550522616" ORDER="76628" O_E="3.019271948608137" SE="0.8209294341779725" STUDY_ID="STD-NASPEAF" TOTAL_1="232" TOTAL_2="235" VAR="1.4838443422426844" WEIGHT="2.9221985491691918"/>
<DICH_DATA CI_END="402.9915960670048" CI_START="0.15782886710016877" EFFECT_SIZE="7.975193230144597" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.605295989516341" LOG_CI_START="-0.8018135608494021" LOG_EFFECT_SIZE="0.9017412143334692" ORDER="76629" O_E="0.5183823529411764" SE="2.0013530153491144" STUDY_ID="STD-PATAF" TOTAL_1="131" TOTAL_2="141" VAR="0.24966208910034604" WEIGHT="0.4916703011105055"/>
<DICH_DATA CI_END="3.6564262797986298" CI_START="0.6185597480459215" EFFECT_SIZE="1.5039009669458712" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.5630568216822105" LOG_CI_START="-0.20861834454996359" LOG_EFFECT_SIZE="0.17721923856612345" ORDER="76630" O_E="1.9860139860139867" SE="0.45328581249845773" STUDY_ID="STD-SPAF-IIa" TOTAL_1="358" TOTAL_2="357" VAR="4.86693725854565" WEIGHT="9.58466908619552"/>
<DICH_DATA CI_END="8.41788897114873" CI_START="0.8465646055290424" EFFECT_SIZE="2.669510602385351" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.9252031932657178" LOG_CI_START="-0.07233989313198547" LOG_EFFECT_SIZE="0.4264316500668661" ORDER="76631" O_E="2.85974025974026" SE="0.5859617468679262" STUDY_ID="STD-SPAF-IIb" TOTAL_1="197" TOTAL_2="188" VAR="2.912470062405127" WEIGHT="5.735652688472505"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6815276343780605" CI_END="1.1516980569348365" CI_START="0.7500144902933069" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.9294031585613282" ESTIMABLE="YES" EVENTS_1="169" EVENTS_2="180" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.06133863412612674" LOG_CI_START="-0.12493034595012262" LOG_EFFECT_SIZE="-0.03179585591199796" METHOD="PETO" NO="8" P_CHI2="0.891218774928092" P_Q="1.0" P_Z="0.5034149480654058" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4475" TOTAL_2="4440" WEIGHT="100.0" Z="0.6691262540830007">
<NAME>Vascular death</NAME>
<GROUP_LABEL_1>Oral anticoagulant</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiplatelet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OAC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours APT</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1549402217832705" CI_START="0.6810055747130129" EFFECT_SIZE="0.8868600394057062" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="120" LOG_CI_END="0.06255950628745745" LOG_CI_START="-0.16684933293715573" LOG_EFFECT_SIZE="-0.05214491332484912" ORDER="76632" O_E="-6.61198926334626" SE="0.13475588775260652" STUDY_ID="STD-ACTIVE-W" TOTAL_1="3371" TOTAL_2="3335" VAR="55.068659019257" WEIGHT="65.92661511757473"/>
<DICH_DATA CI_END="4.683100018839751" CI_START="0.3325972325453364" EFFECT_SIZE="1.2480328945981807" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6705334332820435" LOG_CI_START="-0.4780813687523673" LOG_EFFECT_SIZE="0.09622603226483806" ORDER="76633" O_E="0.4867256637168138" SE="0.6747020204499813" STUDY_ID="STD-AFASAK-II" TOTAL_1="170" TOTAL_2="169" VAR="2.1967264468634973" WEIGHT="2.629857736872149"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="76634" O_E="0.0" SE="0.0" STUDY_ID="STD-ATHENS" TOTAL_1="16" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.522095244872137" CI_START="0.5625109980922576" EFFECT_SIZE="1.4075572143145798" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.5468010960273695" LOG_CI_START="-0.2498689819026711" LOG_EFFECT_SIZE="0.1484660570623492" ORDER="76635" O_E="1.5610278372591004" SE="0.4679679473565929" STUDY_ID="STD-NASPEAF" TOTAL_1="232" TOTAL_2="235" VAR="4.566335155882043" WEIGHT="5.4666851468893425"/>
<DICH_DATA CI_END="2.8110462670696057" CI_START="0.4162609023773823" EFFECT_SIZE="1.0817248521481635" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.44886799372827413" LOG_CI_START="-0.38063437863798266" LOG_EFFECT_SIZE="0.03411680754514575" ORDER="76636" O_E="0.33088235294117574" SE="0.4872537996309048" STUDY_ID="STD-PATAF" TOTAL_1="131" TOTAL_2="141" VAR="4.21201133345676" WEIGHT="5.042498855012306"/>
<DICH_DATA CI_END="1.438260126621823" CI_START="0.43040497293329427" EFFECT_SIZE="0.7867873352245205" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="25" LOG_CI_END="0.15783744052510185" LOG_CI_START="-0.36612271943968827" LOG_EFFECT_SIZE="-0.10414263945729324" ORDER="76637" O_E="-2.53146853146853" SE="0.3077767916079393" STUDY_ID="STD-SPAF-IIa" TOTAL_1="358" TOTAL_2="357" VAR="10.556702039219523" WEIGHT="12.638180130864788"/>
<DICH_DATA CI_END="2.3123013205379594" CI_START="0.5216099425347944" EFFECT_SIZE="1.0982346556765246" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" LOG_CI_END="0.36404442720528946" LOG_CI_START="-0.28265413900381264" LOG_EFFECT_SIZE="0.04069514410073845" ORDER="76638" O_E="0.6493506493506498" SE="0.3798739390007578" STUDY_ID="STD-SPAF-IIb" TOTAL_1="197" TOTAL_2="188" VAR="6.929804773148927" WEIGHT="8.29616301278668"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.202931659209643" CI_END="0.9015313254611288" CI_START="0.6119280793968329" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.7427464792952637" ESTIMABLE="YES" EVENTS_1="188" EVENTS_2="247" I2="9.211890816551689" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="-0.04501917827208219" LOG_CI_START="-0.2132996179795121" LOG_EFFECT_SIZE="-0.12915939812579716" METHOD="PETO" NO="9" P_CHI2="0.332383776132944" P_Q="1.0" P_Z="0.002624184527493447" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3794" TOTAL_2="3761" WEIGHT="100.0" Z="3.008641634542338">
<NAME>Composite outcome: all strokes, myocardial infarction, or vascular death</NAME>
<GROUP_LABEL_1>Oral anticoagulant</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiplatelet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OAC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours APT</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9035223607093696" CI_START="0.596274354653797" EFFECT_SIZE="0.7339940139723584" ESTIMABLE="YES" EVENTS_1="162" EVENTS_2="215" LOG_CI_END="-0.044061094887750715" LOG_CI_START="-0.22455386895687685" LOG_EFFECT_SIZE="-0.13430748192231373" ORDER="76639" O_E="-27.511929615269906" SE="0.10602234894184577" STUDY_ID="STD-ACTIVE-W" TOTAL_1="3371" TOTAL_2="3335" VAR="88.96212666196442" WEIGHT="86.9255878937789"/>
<DICH_DATA CI_END="2.296850244613194" CI_START="0.5577410635672547" EFFECT_SIZE="1.1318337767911293" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="16" LOG_CI_END="0.3611326799759027" LOG_CI_START="-0.253567379492392" LOG_EFFECT_SIZE="0.05378265024175531" ORDER="76640" O_E="0.9498525073746329" SE="0.36107785774604456" STUDY_ID="STD-AFASAK-II" TOTAL_1="170" TOTAL_2="169" VAR="7.670051600664803" WEIGHT="7.4944672478076475"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="76641" O_E="0.0" SE="0.0" STUDY_ID="STD-ATHENS" TOTAL_1="16" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.1521881206368119" CI_START="0.22342510264931156" EFFECT_SIZE="0.5073733823572114" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="0.0615233932230221" LOG_CI_START="-0.6508680338631261" LOG_EFFECT_SIZE="-0.29467232032005203" ORDER="76642" O_E="-3.87473903966597" SE="0.4184622506648405" STUDY_ID="STD-NASPEAF" TOTAL_1="237" TOTAL_2="242" VAR="5.710674765496545" WEIGHT="5.579944858413457"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.186233752011807" CI_END="1.1785096088848632" CI_START="0.8308413884213381" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.9895223896980745" ESTIMABLE="YES" EVENTS_1="270" EVENTS_2="271" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="0.07133312786047905" LOG_CI_START="-0.08048187718834994" LOG_EFFECT_SIZE="-0.004574374663935435" METHOD="PETO" NO="10" P_CHI2="0.822821991663106" P_Q="1.0" P_Z="0.9059786789249707" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4480" TOTAL_2="4447" WEIGHT="100.00000000000001" Z="0.11811229845458754">
<NAME>All cause mortality</NAME>
<GROUP_LABEL_1>Oral anticoagulant</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiplatelet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OAC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours APT</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2300082533117633" CI_START="0.7844849930143207" EFFECT_SIZE="0.9823049506170858" ESTIMABLE="YES" EVENTS_1="159" EVENTS_2="160" LOG_CI_END="0.08990802554974811" LOG_CI_START="-0.10541535993352463" LOG_EFFECT_SIZE="-0.007753667191888296" ORDER="76643" O_E="-1.3562481359976175" SE="0.11473392349922597" STUDY_ID="STD-ACTIVE-W" TOTAL_1="3371" TOTAL_2="3335" VAR="75.96548407075652" WEIGHT="60.411679594379464"/>
<DICH_DATA CI_END="2.5688596151050422" CI_START="0.5876603201376933" EFFECT_SIZE="1.2286646669459576" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="14" LOG_CI_END="0.40974037127642227" LOG_CI_START="-0.23087363262577829" LOG_EFFECT_SIZE="0.08943336932532199" ORDER="76644" O_E="1.454277286135694" SE="0.3762998369826146" STUDY_ID="STD-AFASAK-II" TOTAL_1="170" TOTAL_2="169" VAR="7.06206872547228" WEIGHT="5.6161220893339125"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="76645" O_E="0.0" SE="0.0" STUDY_ID="STD-ATHENS" TOTAL_1="16" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.766636884894905" CI_START="0.6994766234598295" EFFECT_SIZE="1.3911138798048523" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="15" LOG_CI_END="0.4419521626701155" LOG_CI_START="-0.15522679507071732" LOG_EFFECT_SIZE="0.1433626837996991" ORDER="76646" O_E="2.6826722338204583" SE="0.3507858758604811" STUDY_ID="STD-NASPEAF" TOTAL_1="237" TOTAL_2="242" VAR="8.126729473975852" WEIGHT="6.462795348934317"/>
<DICH_DATA CI_END="1.5940185812562024" CI_START="0.34225644398022737" EFFECT_SIZE="0.7386224551549695" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="17" LOG_CI_END="0.20249337960087238" LOG_CI_START="-0.46564836625107014" LOG_EFFECT_SIZE="-0.1315774933250989" ORDER="76647" O_E="-1.9669117647058822" SE="0.39246976886841334" STUDY_ID="STD-PATAF" TOTAL_1="131" TOTAL_2="141" VAR="6.492135578930401" WEIGHT="5.162881791318635"/>
<DICH_DATA CI_END="1.3827925210880854" CI_START="0.5373812192131894" EFFECT_SIZE="0.8620247855492295" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="41" LOG_CI_END="0.14075702197034115" LOG_CI_START="-0.26971751567472185" LOG_EFFECT_SIZE="-0.06448024685219039" ORDER="76648" O_E="-2.553846153846152" SE="0.24111477529444109" STUDY_ID="STD-SPAF-IIa" TOTAL_1="358" TOTAL_2="357" VAR="17.20094674556213" WEIGHT="13.679081970240583"/>
<DICH_DATA CI_END="1.8810197734239682" CI_START="0.5737549065366825" EFFECT_SIZE="1.0388668462774815" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="24" LOG_CI_END="0.27439336091124084" LOG_CI_START="-0.24127358751534433" LOG_EFFECT_SIZE="0.016559886697948226" ORDER="76649" O_E="0.4155844155844157" SE="0.30290531809833854" STUDY_ID="STD-SPAF-IIb" TOTAL_1="197" TOTAL_2="188" VAR="10.898988727722493" WEIGHT="8.66743920579308"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Monotherapy antiplatelet trials</NAME>
<DICH_OUTCOME CHI2="6.791841168908012" CI_END="3.3877636568317335" CI_START="1.0658169701042186" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.9001936733274285" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="16" I2="26.3822596015758" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.5299131046946506" LOG_CI_START="0.02768263086449689" LOG_EFFECT_SIZE="0.2787978677795737" METHOD="PETO" NO="1" P_CHI2="0.23658738818823744" P_Q="1.0" P_Z="0.02955316900462049" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1439" TOTAL_2="1441" WEIGHT="99.99999999999999" Z="2.1760279723660085">
<NAME>Non-CNS bleeds: monotherapy antiplatelet trials</NAME>
<GROUP_LABEL_1>Oral anticoagulant</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiplatelet</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours OAC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours APT</GRAPH_LABEL_2>
<DICH_DATA CI_END="16.06859343603353" CI_START="0.0626058551320218" EFFECT_SIZE="1.0029895477180566" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2059778624693658" LOG_CI_START="-1.2033850480576898" LOG_EFFECT_SIZE="0.0012964072058379557" ORDER="76650" O_E="0.0014903129657227732" SE="1.4152717001823483" STUDY_ID="STD-AFASAK-I" TOTAL_1="335" TOTAL_2="336" VAR="0.49925262248440283" WEIGHT="4.345119055710458"/>
<DICH_DATA CI_END="2.5335197232549773" CI_START="0.10076629610573656" EFFECT_SIZE="0.5052656713286929" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4037242895887819" LOG_CI_START="-0.9966847046261629" LOG_EFFECT_SIZE="-0.29648020751869053" ORDER="76651" O_E="-1.0088495575221237" SE="0.82260717533818" STUDY_ID="STD-AFASAK-II" TOTAL_1="170" TOTAL_2="169" VAR="1.4777977915263527" WEIGHT="12.861639689531307"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="76652" O_E="0.0" SE="0.0" STUDY_ID="STD-ATHENS" TOTAL_1="16" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="38.23515510539339" CI_START="1.5307703928952439" EFFECT_SIZE="7.650440732604471" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="1.5824628562950502" LOG_CI_START="0.18491005380947295" LOG_EFFECT_SIZE="0.8836864550522616" ORDER="76653" O_E="3.019271948608137" SE="0.8209294341779725" STUDY_ID="STD-NASPEAF" TOTAL_1="232" TOTAL_2="235" VAR="1.4838443422426844" WEIGHT="12.914264315934092"/>
<DICH_DATA CI_END="402.9915960670048" CI_START="0.15782886710016877" EFFECT_SIZE="7.975193230144597" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.605295989516341" LOG_CI_START="-0.8018135608494021" LOG_EFFECT_SIZE="0.9017412143334692" ORDER="76654" O_E="0.5183823529411764" SE="2.0013530153491144" STUDY_ID="STD-PATAF" TOTAL_1="131" TOTAL_2="141" VAR="0.24966208910034604" WEIGHT="2.172870911403748"/>
<DICH_DATA CI_END="3.6564262797986298" CI_START="0.6185597480459215" EFFECT_SIZE="1.5039009669458712" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.5630568216822105" LOG_CI_START="-0.20861834454996359" LOG_EFFECT_SIZE="0.17721923856612345" ORDER="76655" O_E="1.9860139860139867" SE="0.45328581249845773" STUDY_ID="STD-SPAF-IIa" TOTAL_1="358" TOTAL_2="357" VAR="4.86693725854565" WEIGHT="42.358158720968135"/>
<DICH_DATA CI_END="8.41788897114873" CI_START="0.8465646055290424" EFFECT_SIZE="2.669510602385351" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.9252031932657178" LOG_CI_START="-0.07233989313198547" LOG_EFFECT_SIZE="0.4264316500668661" ORDER="76656" O_E="2.85974025974026" SE="0.5859617468679262" STUDY_ID="STD-SPAF-IIb" TOTAL_1="197" TOTAL_2="188" VAR="2.912470062405127" WEIGHT="25.34794730645226"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK MODIFIED="2011-03-07 14:28:54 +0000" MODIFIED_BY="Hazel Fraser">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2011-03-07 14:28:54 +0000" MODIFIED_BY="Hazel Fraser" NO="1">
<TITLE MODIFIED="2011-03-07 14:28:51 +0000" MODIFIED_BY="Hazel Fraser">Feedback</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2011-03-07 14:28:54 +0000" MODIFIED_BY="Hazel Fraser">
<P>Feedback received for this review, and other reviews and protocols of anticoagulants, is available on the Cochrane Editorial Unit website at <A HREF="http://www.editorial-unit.cochrane.org/anticoagulants-feedback">http://www.editorial-unit.cochrane.org/anticoagulants-feedback</A>
</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY/>
<FEEDBACK_CONTRIBUTORS/>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES MODIFIED="2008-09-09 15:52:53 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2008-09-09 15:52:53 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-09-09 15:52:33 +0100" MODIFIED_BY="[Empty name]">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-09-09 15:52:53 +0100" MODIFIED_BY="[Empty name]">
<P>The following search strategy, using a combination of controlled vocabulary (MeSH) and free text terms (.tw), was used for MEDLINE and was modified for the other databases.</P>
<P>MEDLINE (Ovid)<BR/>1. atrial fibrillation/<BR/>2. ((atrial or auricular) adj fibrillation).tw.<BR/>3. 1 or 2<BR/>4. exp platelet aggregation inhibitors/<BR/>5. (antiplatelet$ or anti-platelet$ or antiaggreg$ or anti-aggreg$ or (platelet$ adj5 inhibit$) or (thrombocyt$ adj5 inhibit$)).tw.<BR/>6. (alprostadil$ or aspirin$ or dipyridamol$ or disintegrin$ or epoprostenol$ or iloprost$ or ketanserin$ or ketorolac tromethamine$ or milrinone$ or mopidamol$ or pentoxifyllin$ or procainamide$ or ticlopidine$ or thiophen$ or trapidil$).tw.<BR/>7. (acetyl salicylic acid$ or acetyl?salicylic acid or clopidogrel$ or picotamide$ or ligustrazine$ or levamisol$ or suloctidil$ or ozagrel$ or oky046 or oky-046 or defibrotide$ or cilostazol or satigrel or sarpolgrelate or kbt3022 or kbt-3022 or isbogrel or cv4151 or cv-4151 or triflusal).tw.<BR/>8. (Dispril or Albyl$ or Ticlid$ or Persantin$ or Plavix).tw.<BR/>9. exp platelet glycoprotein gpiib-iiia complex/ai, de<BR/>10. (((glycoprotein iib$ or gp iib$) adj5 (antagonist$ or inhibitor$)) or GR144053 or GR-144053 or abciximab$ or tirofiban$ or eftifibatid$).tw.<BR/>11. (ReoPro or Integrilin$ or Aggrastat).tw.<BR/>12. exp Platelet activation/de<BR/>13. exp Blood platelets/de<BR/>14. (sulphinpyrazone or sulfinpyrazone or indobufen).tw.<BR/>15. or/4-14<BR/>16. exp anticoagulants/<BR/>17. anticoagulant$.tw.<BR/>18. (acenocoumarol$ or dicoumarol$ or ethyl biscoumacetate$ or phenprocoumon$ or warfarin$ or ancrod$ or citric acid$ or coumarin$ or chromonar$ or coumestro$ or esculi$ or ochratoxin$ or umbelliferone$ or dermatan sulfate$ or dextran$ or edetic acid$ or enoxaparin$ or gabexate$ or heparin$ or lmwh$ or nadroparin$ or pentosan sulfuric polyester$ or phenindione$ or protein c or protein s or tedelparin$).tw.<BR/>19. (argatroban or tinzaparin or parnaparin or dalteparin or reviparin or danaparoid or lomoparan or org 10172 or mesoglycan or polysaccharide sulphate$ or sp54 or sp-54 or md805 or md-805 or cy222 or cy-222 or cy216 or cy-216).tw.<BR/>20. (Marevan or Fragmin$ or Fraxiparin$ or Klexane).tw.<BR/>21. exp Pipecolic acids/ae, tu<BR/>22. exp Vitamin K/ai<BR/>23. Vitamin K antagonist$.tw.<BR/>24. exp Antithrombins/ae, pd, de, tu<BR/>25. exp Blood coagulation factors/ai, de<BR/>26. exp Blood coagulation/de<BR/>27. (anticoagulat$ or antithromb$).tw.<BR/>28. or/16-27<BR/>29. 3 and 15 and 28<BR/>30. Randomised Controlled Trials/<BR/>31. random allocation/<BR/>32. Controlled Clinical Trials/<BR/>33. control groups/<BR/>34. clinical trials/ or clinical trials, phase i/ or clinical trials, phase ii/ or clinical trials, phase iii/ or clinical trials, phase iv/<BR/>35. double-blind method/<BR/>36. single-blind method/<BR/>37. Therapies, Investigational/<BR/>38. Drug Evaluation/<BR/>39. Research Design/<BR/>40. evaluation studies/<BR/>41. randomised controlled trial.pt.<BR/>42. controlled clinical trial.pt.<BR/>43. clinical trial.pt.<BR/>44. evaluation studies.pt.<BR/>45. random$.tw.<BR/>46. (controlled adj5 (trial$ or stud$)).tw.<BR/>47. (clinical$ adj5 trial$).tw.<BR/>48. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.<BR/>49. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.<BR/>50. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.<BR/>51. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.<BR/>52. (coin adj5 (flip or flipped or toss$)).tw.<BR/>53. latin square.tw.<BR/>54. versus.tw.<BR/>55. (assign$ or alternate or allocat$).tw.<BR/>56. controls.tw.<BR/>57. or/30-56<BR/>58. 29 and 57</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>